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 Bacterial adherence is the first and one of the most important steps in 
bacterial pathogenesis. Adherence to host cell surfaces requires that the bacteria 
recognize specific receptors in the surface of epithelial cells. Therefore, agents 
that act as molecular decoys to interfere with adherence could be useful 
prophylactic treatments to prevent or mitigate the onset of infections. The goal of 
this research was to assess the ability of several food grade non-digestible 
oligosaccharides (NDOs) to act as molecular decoys and prevent bacterial 
adherence in vitro as well as in vivo. First, the antiadherence effect of specific 
species of chitooligosaccharides (CHOS) at different concentrations was tested 
against enteropathogenic Escherichia coli (EPEC). Microscopic evaluation 
indicated that CHOS reduce adherence of EPEC to HEp-2 cells by more than 
90%. Subsequently, the antiadherence activity of lactoferrin, alone and in 
combination with a 1:1 mix of galactooligosaccharides (GOS) and polydextrose 
(PDX), was tested against Cronobacter sakazakii. Adherence was assessed by 
quantitative PCR (qPCR) and results indicate that lactoferrin inhibits adherence 
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of C. sakazakii to HEp-2 cells at a minimum concentration of 10mg/ml. 
Lactoferrin combined with the GOS:PDX mix did not further inhibit adherence, 
suggesting there is not an additive effect between lactoferrin and GOS:PDX. 
Moreover, the ability of GOS to reduce adherence was assessed in vivo in a 
Citrobacter rodentium mouse model of infection. Conventional and germ free 
C57Bl/6 mice were supplemented with GOS in the drinking water to receive a 
dose of 5000mg of GOS/kg of body weight (daily), for two weeks prior to infection 
and during the course of infection (10 days). At necropsy, adherence and 
disease severity were assessed in the distal colon. Results indicated that GOS 
reduces adherence of GOS in conventional mice but not in germ free mice. 
Nevertheless, the lesions were not improved in mice supplemented with GOS as 
compared to the control. Finally, the antiadherence effect of yeast derived 
mannan oligosaccharides (MOSy) was tested against Vibrio cholerae. Adherence 
inhibition was observed at a minimum concentration of 2mg/ml and reached its 
maximum at 4mg/ml. These results show that different NDOs may be used as a 
prophylactic treatment to prevent adherence, hence preventing or mitigating 
infections by enteric pathogens. 
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Preface 
This thesis is comprised of six chapters. Chapter 1 provides a review of the 
current literature on the biological properties of non-digestible oligosaccharides. 
Chapter 2 describes our published (Quintero-Villegas et al. 2013 Journal of 
Agricultural Food Chemistry) results focusing on the antiadhesive effect of 
chitooligosaccharides (CHOS), against enteropathogenic Escherichia coli. 
Chapter 3 describes our published (Quintero-Villegas et al., 2014 Current 
Microbiology) results obtained when testing the antiadherent effect of lactoferrin 
alone and in combination with a mix of galactooligosaccharides (GOS) and 
polydextrose (PDX) against Cronobacter sakazakii. Chapter 4 describes results 
on the antiadherent effect of GOS against Citrobacter rodentium in an in vivo 
mouse model (conventional flora and germ free). Chapter 5 describes the results 
obtained when testing the anti-adherence effect of yeast derived mannan 
oligosaccharides (MOSy) against Vibrio cholerae at different doses, as wells as 
the results obtained from in vitro MOSy fecal fermentations. Finally, Chapter 6 
provides a conclusion section that summarizes the major research findings 
presented within this dissertation, in addition to future experiments proposed. 
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Chapter 1 
Non-digestible Oligosaccharides: Food Ingredients Targeted to Host Health
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Abstract 
Novel food ingredients that contribute to host health, beyond the nutritional value, 
have now attracted much attention and represent a very evident trend: food 
ingredients that improve health are now preferred. Non-digestible 
oligosaccharides (NDOs) are food ingredients that have been shown to have 
different biological properties, and contribute to host health upon consumption. 
NDOs have the ability to modulate the gut microbiota, stimulating the growth of 
beneficial members and hence increasing the production of short chain fatty 
acids (SCFA); modulate immune responses, either direct or indirect; and serve 
as anti-adherence agents that are capable of blocking pathogen adherence to 
the surface of epithelial cells. This review describes the different biological 
properties that have been shown for some NDOs of interest, focusing mainly on 
the immunomodulatory potential and anti-adherence effect in vivo. 
Key words: Non-digestible oligosaccharides, gut microbiota, anti-adherence, 
adhesins, immune modulation 
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Introduction 
Among the novel food ingredients that have received much research and 
commercial attention due to their biological properties are the non-digestible 
oligosaccharides (NDO). NDOs are found naturally in plant material and can be 
obtained or derived from other natural sources including yeast, bacteria, fungi, 
shellfish, and milk. Commercially, they are most often derived chemically or 
enzymatically from the hydrolysis of natural polymers, synthesized from 
monomers, or extracted directly from natural sources (Boehm and Moro, 2008). 
The best-studied NDOs include the galactooligosaccharides (GOS), 
fructooligosaccharides (FOS), inulin, and mannan oligosaccharides (MOS). 
These are commercially available and some are now being included as prebiotics 
or supplements for human and animal food applications.  
This review provides a short overview of the composition and structure of some 
NDOs of interest, as well as the biological properties that have been attributed to 
them. These include the prebiotic activity, in addition to the ability to reduce 
adherence of pathogens in vitro and in vivo, and the immune-modulatory 
potential of some of these NDOs. 
Composition and structure of NDOs 
In general, NDOs are short-chain, low molecular weight carbohydrates defined 
by having a degree of polymerization (DP) ranging from 3 – 10 in most cases 
(Mussatto and Mancilha, 2007). Some oligosaccharides, such as inulin derived 
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from chicory and other root sources, can have a DP of up to 60, while others like 
lactulose can be as small as DP2. NDOs are, by definition, resistant to acid 
hydrolysis and to enzymes present in saliva and the digestive tract, hence they 
reach the colon intact. The anomeric carbon (C1 or C2) of the monosaccharide 
units of the NDOs is configured such that the glycosidic bonds are resistant to 
human digestive enzymes (Roberfroid and Slavin, 2000). Nevertheless, they are 
potentially hydrolyzed by enzymes produced by colonic bacteria (Swennen et al., 
2006). In addition, many have been categorized as functional food ingredients, 
which are defined as food ingredients that provide a health benefit beyond any 
nutritional value (Gosling et al., 2010).  
Galactooligosaccharides (GOS) 
GOS are synthesized enzymatically from lactose by β-galactosidases that have 
both hydrolytic and transgalactosylating activity. During the transgalactosylation 
reaction, galactose monomers are added to lactose to produce oligomers of 
varied DP, ranging from DP2 to DP10, all with a terminal glucose.  The resulting 
linkages include β(1-3), β(1-4), and β(1-6). Structural differences in the GOS 
molecules can result in different biological properties when assessed in vitro and 
in vivo (Gosling et al., 2010). 
Inulin and Fructooligosaccharides (FOS) 
Inulin and FOS are part of a larger group of carbohydrates called fructans. To be 
considered a fructan, one or more of the glycosidic bonds should contain 
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fructosyl-fructose linkages, primarily forming polymers of fructose units. Fructans 
can be linear or branched, and are often described by the type of glycosidic 
linkages and DP (Kelly, 2008). 
Inulin is a linear fructan with β(2-1) fructosyl-fructose linkages (Roberfroid, 2007; 
Waterhouse and Chatterton, 1993); some can have a starting glucose molecule. 
The most common source of inulin for commercial production is chicory root, and 
chicory inulin configuration usually ranges from DP2 to about DP60; the average 
DP (DPav) is 12 (Roberfroid, 2005). Only a small percentage is in the range of 
DP2 to DP4. Inulin can also be synthesized from sucrose. In this case all the 
resulting molecules start with a glucose unit and the DP ranges from 2 to 4. 
These are classified as inulin-type fructans called FOS (Kelly, 2008; Roberfroid, 
2007). Although the definition of FOS is not consistent in the NDOs literature, 
FOS can be used to describe short-chain, inulin-type fructan mixes, whereas 
inulin-type fructans that are derived from the partial hydrolysis of inulin are often 
referred to as oligofructose. Nonetheless, both compounds must have DP<10 
(Kelly, 2008).   
Chitooligosaccharides (CHOS) 
CHOS are produced enzymatically or chemically from chitosan.  The latter is a 
heteropolymer of glucosamine (GlcN) and N-acetyl glucosamine (GlcNAc), with 
varying DP (commonly DP<10) (Jeon and Kim, 2000) and degrees of acetylation 
(FA); chitosan and its derivatives are β(1-4) linked (Vander, 1998).  
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The structures of the CHOS rely strongly on the type of enzyme used in the 
hydrolysis process. The specific cleavage sites of chitinases or chitosanases are 
determined by the sequences in the heteropolymers of GlcNAc and GlcN 
(chitosans), hence yielding different combinations of CHOS. These will vary with 
respect to length and sequence features (Aam et al., 2010); they can be defined 
by their FA, DP, and the pattern of N-acetylated sugar residues (Quintero-Villegas 
et al., 2013).  
Pectin oligosaccharides (POS) 
Pectin is a structural component in the primary cell walls of plants such as fruits 
and vegetables. Structurally, it is comprised mainly of three major 
polysaccharides: homogalacturonan (HG), rhamnogalacturonan-I (RG-I), and 
rhamnogalacturonan-II (RG-II); these are galacturonic acid-rich polysaccharides 
(Fanaro et al., 2005; Willats et al., 2001). POS are derived from de-
polymerization of pectin rich products or by-products, and are acidic 
oligosaccharides due to the nature of the polysaccharide from which they are 
derived. They can be obtained from products such as sugar beet pulp, apple 
pomace, and citrus peel, by either chemical or enzymatic processing (Gullón et 
al., 2013; Martínez-Sabajanes et al., 2012).  
HG structure is comprised of a galacturonic acid backbone with α(1-4) linkages, 
containing free or esterified carboxyl groups, which can be partly substituted. 
RG-I is a branched polymer with alternating units of galacturonic acid and 
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rhamnose. In addition, branches of arabinan, galactan, and arabinogalactan can 
be attached. RG-II is a complex branched polymer of galacturonic acid, 
rhamnose, and galactose, in addition to some unusual sugars (Gullón et al., 
2013; Martínez-Sabajanes et al., 2012; Ralet et al., 2005).  
Mannan oligosaccharides (MOS) 
Yeast cell walls as well as other natural sources, including plant material, are rich 
in mannan polysaccharides. Yeast cell walls contain an α(1-4) linked mannose 
monomer backbone, and many carry N-linked glycans with a high-mannose core 
(Gemmill and Trimble, 1999). There are different structural arrangements of 
mannans found in nature, and each seem to be characteristic to the organism or 
source from which it comes (Kocourek and Ballou, 1969). MOSs result from the 
partial hydrolysis of mannan polysaccharides and are, in general, glucomannan 
complexes comprised of α(1-4) linked mannose monomers (Dimitroglou et al., 
2009). 
Human milk oligosaccharides (HMO) 
The carbohydrate fraction of human milk (7%) consists of lactose, and a complex 
mixture of oligosaccharides that has recently been characterized (Coppa et al., 
1993; Kunz et al., 2000). Approximately 200 different molecular species have 
now been identified (Ben et al., 2004; Coppa et al., 1993; Kunz et al., 2000; 
Zivkovic et al., 2010).   This structural diversity is due, in part, to the presence of 
several functional groups, including fucose and sialic acid residues. Identified 
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HMOs are comprised of neutral and acidic oligosaccharides, with fucose and 
sialic acid units at the terminal ends (Ninonuevo et al., 2006) with N-acetyl-
lactosamine units (Zivkovic et al., 2010).  
Many of these oligosaccharides have no nutritional value, but they have been 
shown to have other biological properties that confer health benefits upon 
consumption. In addition, some have similar structures to those found in the 
surface of intestinal cells (Sharon and Ofek, 2000, 2002), a property that can be 
protective against pathogen colonization (Kunz et al., 1999; Sharon and Ofek, 
2000). 
Biological Properties 
Important biological properties have been attributed to NDOs. In particular, 
several NDOs have been classified as prebiotics, due to their selective 
fermentation by beneficial microorganisms in the gastrointestinal tract. The ability 
of NDOs to modulate the gut microbiota has been extensively studied in vitro as 
well as in human and animal studies.  Despite differences in the monomer 
content, linkages, and DP, most prebiotic NDOs are able to promote or stimulate 
the growth of beneficial members of the gut microbiota, including bifidobacteria 
and lactobacilli (Boehm et al., 2004; Gibson and Roberfroid, 1995; Veereman-
Wauters, 2007). Among the studies of NDOs with human subjects, Davis et al., 
2010 evaluated the effect of different doses of GOS on the gastrointestinal 
microbiota of healthy adults. Results indicated that supplementation of 5g of 
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GOS or higher, on a daily basis, resulted in an increase in the number of 
bifidobacteria in some, but not all subjects. The efficacy of FOS in modulating the 
gut microbiota was evaluated by Tuohy et al., 2001. 7 g/day of FOS were 
delivered in shortbread biscuits and the changes in gut microbiota were 
assessed by 16s sequencing. Results indicated that FOS conferred a bifidogenic 
effect upon consumption. Other studies, in vitro and in vivo, regarding the 
bifidogenic effect of prebiotics are discussed in more detail in Gibson et al., 2004 
and Roberfroid, 2007.  
In addition to their prebiotic activity, some NDOs have also been reported to 
modulate the immune system, either directly or indirectly (Buddington et al., 
2007; Meijer et al., 2010).  Finally, NDOs have been suggested to act as 
therapeutic agents for preventing or mitigating bacterial infections, due to their 
ability to inhibit pathogen binding to the surface of epithelial cells (Quintero et al., 
2011; Quintero-Villegas et al., 2013; Shoaf et al., 2006). These latter two 
properties will be discussed in more detail in this review. 
Adherence 
The ability of NDOs to inhibit pathogen binding to the surface of epithelial cells 
has attracted considerable interest for more than 20 years. Bacterial adherence 
to host cell surfaces is the first and, in many cases, the most important, step in 
bacterial pathogenesis (Bavington and Page, 2005; Klemm et al., 2010; Shoaf et 
al., 2006). Adherence is the mechanism by which bacteria are able to avoid the 
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host’s natural displacement mechanisms (peristalsis, acid excretion, flux, etc.). In 
addition, adherence to the epithelial cell surface provides access to open niches 
(not colonized by commensal bacteria), as well as access to nutrients located at 
the epithelial cell surface, hence improving the potential for colonization and 
infection (Kamada et al., 2013; Ofek et al., 2003a; Sinclair et al., 2009). Bacteria 
that are not able to express functional adhesins are, in many cases, incapable of 
initiating infection (Boddicker et al., 2002; Cleary, 2004). Several biological 
events occur during the interaction between infectious bacteria and the host. In 
general, physical forces bring the bacteria closer to its target host cell surface 
(Busscher, 1987), followed by hydrophobic interactions that reversibly bind the 
bacteria to the target cell receptor (Ofek et al., 2003b). Subsequently, a much 
stronger interaction takes place. This interaction is formed between specific 
bacterial adhesins and their complementary host cell surface receptors (Abu-Lail 
and Camesano, 2003; Cozens and Read, 2012; Pinzón-Arango et al., 2009).  
Blocking adherence should reduce the colonization potential of a pathogen. 
Hence, agents that block pathogen adherence, such as NDOs, have gained 
considerable interest.  
Bacterial Lectins 
Many bacterial adhesins are lectin-like components that recognize specific 
carbohydrate moieties on host cell surfaces; they are usually organized in thread-
like organelles called fimbriae or pili (Bavington and Page, 2005; Klemm et al., 
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2010; Sharon, 2006). Not surprisingly, a great number of pathogens produce 
these structures (Foster, 2004; Odenbreit, 2005; Pizarro-Cerdá and Cossart, 
2006). Due to their receptor specificity, adhesins are the primary reason why 
tissue tropism exists among different bacterial species. Their receptor specificity 
is determined by structural differences between different lectins, which are 
dependent on the small globular carbohydrate-recognition domains. Slight 
chemical differences in these domains  allow for the selectivity and specificity of 
each adhesin to its target receptor (Shoaf-Sweeney and Hutkins, 2008; Weis and 
Drickamer, 1996). Thus, the specific binding of a pathogen to a particular tissue 
or host is dependent on the particular carbohydrate receptors coating the 
epithelial cell surface (Klemm and Schembri, 2000; Shoaf-Sweeney and Hutkins, 
2008). Certainly, adhesins are considered a primary virulence factor for many 
bacterial pathogens; they are required for infection of different tissues of the 
mammalian host (Connell et al., 1997; Klemm et al., 2006, 2007). Bacterial 
pathogens are capable of expressing more than one adhesin, nevertheless, they 
are often expressed at different stages of infection (Klemm et al., 2010).  
Lectins are identified as the primary type of bacterial adhesin (Sharon and Ofek, 
2000). Several adhesins have been identified for different pathogenic bacteria as 
well as some specific carbohydrate receptors. Nevertheless, due the complexity 
of the techniques required, the interactions between the adhesin and its specific 
carbohydrate receptor needs further study (Choudhury, 1999; Dodson et al., 
2001). 
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Fimbrial Architecture and Adhesins 
Placing receptor-specific lectins at the cell surface can be a challenge, 
nevertheless bacteria have developed numerous ways and a variety of adhesins 
and structures exist (Klemm and Schembri, 2000). As noted above, the majority 
of bacterial adhesins are arranged in organelles called fimbriae or pili. These are 
filamentous appendages that are localized on the bacterial surface. In Gram-
negative bacteria, they are anchored to the outer membrane and are comprised 
of several different subunits (Gerlach and Hensel, 2007).  
There are several different types of fimbriae among bacterial species. Generally, 
they are heteropolymers of about 1 µm in length. The fimbrial adhesins are 
located at the tip of the organelle, where a structural protein displays the adhesin 
(Klemm and Schembri, 2000; Klemm et al., 2010). Based on structural 
differences, fimbriae have been classified in different categories. In most cases 
intestinal and extra-intestinal pathogens use different types of fimbriae and 
adhesins due to the differences in the tissue to which they adhere. Table 1 
describes the main adhesins found in intestinal and extra-intestinal pathogens of 
interest.   
Anti-adherence 
Bacterial adhesins recognize specific carbohydrate moieties on the surface of the 
epithelium, to which they tightly bind. Some of these receptors that are 
recognized by different pathogens have been identified and their structures are 
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known (Table 2). Interestingly, several NDOs have been shown to have similar 
structures to the carbohydrate moieties that are located on the surface of 
epithelial cells and that are recognized as pathogen binding sites. Hence, these 
NDOs could act as molecular decoys that can prevent the initial binding of 
pathogens to the surface of cells (Sharon and Ofek, 2000, 2002; Shoaf-Sweeney 
and Hutkins, 2008). This binding interference could therefore result in the 
prevention or mitigation of the onset of an infection. Many in vitro studies have 
shown the ability of NDOs to inhibit pathogen adherence to tissue culture cells 
(Table 3). 
Several in vivo models have also been used to assess the anti-adherence effect 
of NDOs. Manthey et al., 2014 used a suckling mice model to test the role of 
HMOs and GOS in preventing enteric infections; enteropathogenic Escherichia 
coli (EPEC) was used as a model of infection. Newborn mice were infected orally 
with EPEC with or without pre-incubation with HMOs or GOS. In addition some 
groups were gavaged with GOS, HMO, or PBS before and after infection. 
Results showed that HMOs were effective at reducing EPEC colonization in 
suckling mice, when administered at the day of infection and throughout the 
infection period. Interestingly, GOS did not show any significant differences in 
EPEC colonization rates as compared to the PBS control mice.  
Liu et al., 2010 used a pig model to assess the ability of CHOS to reduce clinical 
signs associated with E. coli K88 infection. Weaned pigs were fed either a corn-
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soybean meal diet or the same diet supplemented with CHOS, and both groups 
were then challenged with E. coli K88. Pigs supplemented with CHOS had 
decreased incidence of diarrhea and lower E. coli K88 counts in the small and 
large intestine, compared to the un-supplemented diets. Nevertheless, the 
growth performance of E. coli K88-challenged pigs supplemented with CHOS 
was not significantly different from pigs that were not given CHOS. Hence, 
although CHOS was able to reduce E. coli colonization, it did not appear to be a 
suitable growth promoter.  
Searle et al., 2009 studied the ability of GOS to protect from a Salmonella 
enterica serovar Typhimurium infection a BALB/c mouse model. GOS, or saline 
solution as a control, was gavaged prior to challenge with S. Typhimurium. The 
delivery of GOS prior to challenge resulted in significant reductions in 
colonization. Additionally, they showed that the presence of GOS in a murine 
ligated ileal loop model prevented colonization by S. Typhimurium and its 
associated pathology. In a subsequent study, Searle et al., 2010 confirmed the 
results from the previous study by assessing the effect of the basal ingredients of 
GOS in the same mouse model. Results indicated that only the groups that were 
supplemented with GOS prior to challenge with S. Typhimurium showed reduced 
colonization as compared to the control.  
Ruiz-Palacios et al., 2003 tested the efficacy of HMOs to inhibit colonization by 
Campylobacter jejuni in BALB/c mice. Mice were challenged with either 104 or 
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108 CFU of C. jejuni, and were supplemented with a total of 6 mg of neutral 
HMOs delivered in three doses: 2 hours before, during, and after oral challenge 
with C. jejuni. In addition, they tested C. jejuni colonization in transgenic mice 
pups that carried the human fucosyltransferase gene (FUT1), which results in 
expression fucosyl α(1-2) ligand in the mammary gland tissue of lactating mice. 
As a result, the milk of the lactating mice contains H-2 group blood antigen. 
Transgenic pups were inoculated with three different doses of C. jejuni, as were 
pups from conventional (wild-type) mice as a control. Results indicated that mice 
supplemented with HMOs were colonized at a significantly lower level by C. 
jejuni. In the transgenic mouse model, transgenic mice pups cleared the C. jejuni 
infection quicker than conventional (wild-type) mice over the course of study. For 
each inoculum, colonization levels in transgenic mice were significantly lower 
than those in conventional (wild-type) mice.  
Umar et al., 2003 tested the ability of 6% pectin in the diet, compared to a fiber 
free diet, to ameliorate C. rodentium infection in Swiss-Webster mice. Signs of 
colonic hyperplasia, such as crypt length, were assessed. Results indicated that 
pectin supplementation in the diet ameliorated some of the disease pathology. 
Pectin reduced increases in cell proliferation and crypt length, as well as it 
reduced β-catenin, cyclin D1, and c-myc levels, which are molecules associated 
with C. rodentium infection.  
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Wang et al., 2001 used BALB/c mice to evaluate the efficacy of bovine milk 
glycoconjugates to inhibit adherence of Helicobacter pylori 317p. Bovine milk 
glycoconjugates were delivered in a dose of 4000mg/kg of body weight. Results 
indicated that mice that were given the glycoconjugates had reduced rates of H. 
pylori gastric colonization as well as lower inflammation scores as compared with 
the H. pylori-infected control mice.  
Mysore et al., 1999 used 3’sialyllactose (3’SL), an oligosaccharide that occurs 
naturally in bovine colostrum and human milk, to treat H. pylori-infected rhesus 
monkeys. 3’SL was supplemented alone or in combination with proton pump 
inhibitors (PMP) to determine if these would increase the efficacy. In a portion of 
the monkeys treated with 3’SL, H. pylori infection was not detected, nevertheless, 
the addition of PMP did not seem to play a role in helping eradicate H. pylori from 
the monkeys.  
A rabbit model of pneumonia was used by Idänpään‐Heikkilä et al., 1997 to 
evaluate the efficacy of different oligosaccharides to inhibit adherence of 
Streptococcus pneumoniae when administered together via intra-tracheal 
instillation. Bacterial quantitation was obtained from bronchoalveolar lavage fluid 
(BAL) 48 hours after challenge. Oligosaccharides tested included: LNnT (Gal 
β(1–4) GlcNAc β(1–3) Gal β(1–4) Glc), LSTc (Neu5Ac α(2–6) Gal β(1–4) GlcNAc 
β(1–3) Gal β(1–4) Glc), 3’SLNnT (Neu5Ac α(2–3) Gal β(1–4) GlcNAc β(1–3) Gal 
β(1–4) Glc), 3’SLn (Neu5Ac α(2–3) Gal β(1–4) GlcNAc), 3’GL (GalNAc β(1–3) 
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Gal β(1–4) Glc); these were chosen as a representative range of specific 
adherence moieties of S. pneumoniae on respiratory tract cells.  All but 3’SLn 
and 3’GL reduced S. pneumoniae counts of BAL as compared to the control 
group, protecting the rabbits from bacteremia. A rat nasopharyngeal colonization 
model was included in this study. Infant Sprague-Dawley rats were challenged 
with 106 S. pneumoniae, intranasally. Intranasal supplementation of 
oligosaccharides, along with the bacteria, prevented colonization of the 
nasopharynx.  
Mouricout et al., 1990 tested glycoprotein glycans in the ability to reduce 
adherence of enterotoxigenic E. coli (ETEC) to the intestinal cells of newborn 
calves that had been colostrum deprived. Glycoprotein glycans were obtained 
from bovine plasma, and the glycan moieties used were shown to mimic the 
oligosaccharide moieties recognized by the E. coli K99 pili. Newborn calves were 
inoculated with approximately 1010 ETEC and supplemented with more than 
500mg of glycan preparation per day. Results indicated that calves treated with 
glycans had fewer ETEC cells adhered to the intestines, specifically to 
duodenum, jejunum, and ileum sections.  
Aronson et al., 1979 tested methyl α-D-mannopyranoside (αMM), known to 
interfere with mannose binding in E. coli, for its ability to prevent urinary tract 
infections in a mouse model. αMM was injected along with the bacterium. As a 
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result, mice treated with αMM exhibited a reduction in the number of mice with 
bacteremia.  
In vitro and in vivo studies support the idea that different NDOs can block 
pathogen attachment to the surface of epithelial cells. Although further studies 
are required that involve different pathogens, and a variety of NDOs, these are 
the first approaches to alternative prophylactic methods to prevent an onset of 
infection.  
Although it has been shown that NDOs can prevent and/or reduce bacterial 
adherence in animal models, only two studies using humans as a subject have 
been reported. In spite of results from animal models being indeed very 
promising, the human trials have not proven as successful. In a clinical trial by 
Ukkonen et al., 2000, more than 500 children 10 to 24 months old received 3-
sialyllacto-N-neotetraose (NeuAc2-3Galβ1-4GlcNAcβ1-3Galβ1-4Glc) as a 
prophylactic treatment to reduce nasopharyngeal colonization and disease 
caused by Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus 
influenzae, as well as the  incidence of acute otitis media. The treatment was 
administered by nasal spray (2mg in each nostril per day) for 3 months. The 
treatment did not reduce carriage of any of the three pathogens of interest, and 
did not show any beneficial effect on the occurrence of acute otitis media. In 
another trial by Parente et al., 2003, 3’sialyllactose (10 or 20 g/day) was 
administered to 61 patients to reduce colonization of H. pylori. Although the 
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treatment was well-tolerated and did not present any side effects, it was not 
effective at clearing off patients from H. pylori colonization. The study by Mysore 
et al., 1999 with rhesus monkeys showed that although some of the subjects 
were cleared off H. pylori colonization, the treatment was not effective in all of the 
monkeys that were treated.  
Immune modulation 
Several NDOs have been reported to modulate the immune system (Buddington 
et al., 2007; Guigoz et al., 2002; Meijer et al., 2010; Watzl et al., 2007). In 
general, immune modulation occurs indirectly and is mediated via selective 
stimulation of specific members of the gut microbiota, in particular, species of 
Bifidobacterium and Lactobacillus. Many of these organisms ferment NDOs and 
can produce short chain fatty acids (SCFA), such as acetate, butyrate, and 
propionate, which play an important role in the gut.  Butyrate, for example, has 
been extensively studied and has been identified as an important immune 
modulator (Gourbeyre et al., 2011). SCFAs are absorbed from the colonic lumen 
and serve as an energy source for colonic epithelial cells. A fraction of the 
produced SCFAs are released into the bloodstream (Meijer et al., 2010).  
Immune cells carry receptors that are believed to be responsible for the 
interactions with SCFAs; these are the G protein-coupled receptors (GPR). 
GPR41 and GPR43 are recognized as the main SCFA receptors; both are 
expressed on immune cells (Le Poul et al., 2003). Receptors are activated by 
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different SCFAs, and the efficacy of the activation varies depending on the 
SCFA. For example, GPR41 will be activated by propionate, butyrate, and 
acetate, with the activation by propionate being 100 fold more potent than that of 
acetate (Le Poul et al., 2003). 
Cytokine production derived from the stimulation of leukocytes by SCFAs, 
especially butyrate, has been reported (Hamer et al., 2008; Säemann et al., 
2000).  Butyrate has been shown to induce a shift from a pro-inflammatory Th1-
like response to an anti-inflammatory profile, upon stimulation with agents that 
induce inflammation such as lipopolysaccharide (LPS) (Maa et al., 2010; Park et 
al., 2007; Säemann et al., 2000). Investigators have suggested that one of the 
mechanisms by which butyrate exerts an anti-inflammatory profile is mediated by 
signaling pathways such as NF-κB (Park et al., 2007; Segain, 2000; Usami et al., 
2008).  Propionate and acetate have also been shown to inhibit NF-κB reporter 
activity in a dose dependent manner as well as to decrease TNF-α release from 
neutrophils, when stimulated with LPS (Tedelind et al., 2007). 
Another effect of SCFA in immune modulation is related to chemotaxis. Acetate, 
butyrate, and propionate have been shown to increase the chemotactic response 
of neutrophils, as well as an increased expression of L-selectin in the surface of 
the latter. The concentration of the different SCFA is important, since it was 
shown that higher concentrations do not exhibit any chemotactic effect as 
compared with the lower concentrations used in the studies (M et al., 2009; Sina 
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et al., 2009). As expected, the effect of SCFA in chemotaxis depends on the type 
of SCFA and the concentration at which it is tested. In addition, different immune 
cell types will exhibit a different response upon stimulation with SCFAs (Meijer et 
al., 2010).  
The immunomodulatory potential of NDOs does not rely solely on the modulation 
of the gut microbiota resulting in the increased production of SCFA. Other studies 
have been reported in which an immunomodulatory potential of NDOs is shown 
without necessarily being linked to SCFA production. Some of the most recent in 
vivo animal studies are summarized in Table 4.  
Conclusion 
NDOs have been shown to have different biological properties beneficial to the 
host upon consumption. Whether direct or indirect, the beneficial effects reported 
have raised considerable interest towards NDOs as functional food ingredients. 
The modulation of the gut microbiota, the use as anti-adherence agents with 
prophylactic purpose, and their immunomodulatory potential are desirable traits 
in a functional food ingredient.  Although further research is needed, especially to 
determine if they could be used as prophylactic agents to prevent bacterial 
infections, promising results have already been shown that serve as a basis to 
advance in the field. A profound characterization of the factors affecting 
expression of adhesins during the course of an infection, and identifying the 
types of adhesins, should lead to a better understanding of bacterial adherence 
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and the development of anti-adherence agents that could be applied to prevent 
infections.  
In conclusion, there is enough evidence that NDOs can confer benefits to the 
host upon consumption. As the field advances, NDOs can be recognized as 
promising therapeutic agents to prevent bacterial infections and promote health. 
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Table 1. Fimbrial adhesins of intestinal and extra-intestinal pathogens. Description of architecture and fimbrial 
adhesin characteristics. 
Fimbrial 
Adhesins 
 
Architecture and 
Characteristics 
Present in References 
Pyelonephritis 
Associated 
Fimbriae (P) 
PapG adhesin 
Outer Membrane 
Assembled via Chaperone 
Usher (CU) Pathway 
Encoded in the pap operon 
 
Escherichia coli (Dodson et al., 2001; Gerlach and 
Hensel, 2007; Saulino et al., 2000; 
Strömberg et al., 1990; Vetsch et 
al., 2004) 
Type I Fimbriae Encoded in fim operon 
FimH is the fimbrial adhesin 
FimH main binding receptor: 
uroplakin 
Assembled via CU pathway 
Escherichia coli 
Salmonella Typhimurium 
Salmonella Enteritidis 
Klebsiella pneumoniae 
 
(Gerlach and Hensel, 2007; Jones, 
1995; Krogfelt et al., 1990; Shoaf-
Sweeney and Hutkins, 2008; Wu, 
1996; Xia et al., 2000; Zhou et al., 
2001) 
CS Fimbriae 
 
Assembled via alternate CU 
pathway 
Enterotoxigenic 
Escherichia coli (ETEC) 
 
(Gerlach and Hensel, 2007; Soto 
and Hultgren, 1999) 
 
 
 
 
4
6
 
Type IV 
Fimbriae 
Pilin protein adhesin 
Polymerization of subunits in 
cytoplasmic membrane 
Two sub-groups: type IVa and 
type IVb (based on amino acid 
sequence) 
Differ in diameter and helical 
structure 
 
Neisseria gonorrhoeae 
Neisseria meningitides 
Moraxella bovis 
Pseudomonas 
aeruginosa 
Vibrio cholerae 
 
(Craig et al., 2004; Smyth et al., 
1996; Tennent and Mattick, 1994) 
Curli 
 
Thin coiled fibers 
Biofilm formation  
Adherence to human matrix and 
plasma proteins and major 
histocompatibility complex 
(MHC) class I molecules 
Outer membrane protein CsgA 
essential for optimal curli 
assembly 
Assembled via extracellular 
nucleation-precipitation pathway 
Salmonella spp. 
Escherichia coli spp. 
 
(Nasr et al., 1996; Olsen et al., 
1998; Robinson et al., 2006) 
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Long Polar 
Fimbriae (Lpf) 
Adhesion to Peyer’s patches 
Assembled via CU pathway 
Salmonella Typhimurium 
Salmonella Enteritidis 
 
(Baumler et al., 1996; Bäumler et 
al., 1997) 
Thin 
Aggregative 
Fimbriae (Tafi) 
Assembled via the nucleation 
precipitation pathway 
Adhesins with a diameter of 3-4 
nm  
Used for auto-aggregation 
Expressed in response to 
nutrient limitation, low 
osmolarity and temperature 
Salmonella spp. (Collinson et al., 1991, 1993) 
Bundle forming 
pili (BFP) 
Type IV pilus 
Encoded on Enteropathogenic 
Escherichia coli (EPEC) 
adherence factor (EAF) plasmid  
Bacteria-bacteria interaction and 
microcolony formation 
Initial EPEC binding to epithelial 
cells 
EPEC (Donnenberg et al., 1992; Giron et 
al., 1991; Tobe and Sasakawa, 
2001) 
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8
 
F17 Fimbriae 3 nm wide 
Major pilin subunit: F17-A 
F17-G expressed on the tip 
Mediate binding to N-
acetylglucosamine receptors on 
microvilli of ruminants’ intestinal 
epithelia 
Enterotoxigenic E. coli 
(ETEC) 
 
(Buts et al., 2004; Sharon, 2006) 
Diffuse 
Adherence 
Fibrillar 
Adhesin 
(Afa/Dr) 
Assembled via CU pathway Diffusely adhering 
Escherichia coli (DAEC) 
 
(Gerlach and Hensel, 2007; 
Servin, 2005) 
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Table 2. Carbohydrate moieties identified as pathogen binding sites on animal 
tissues. Adapted from Ernst and Magnani, 2009; Ofek et al., 2003b; Sharon, 
2006. 
 
 
Organism /Fimbriae Carbohydrate Moieties 
Campylobacter jejuni Fucα2GalβGlcNAc 
Escherichia coli 
Type 1 
P Fimbriae 
S Fimbriae 
CFA/1 
F1C 
F17 
K1 
K99 
 
Manα3Manα6Man 
Galα4Gal 
NeuAc (α2–3)Galβ3GalNAc 
NeuAc (α2–8) 
GalNAcβ4Galβ 
GlcNAc 
GlcNAcβ4GlcNAc 
NeuAc(α2–3)Galβ4Glc 
Haemophilus influenzae [NeuAc(α2–3)]0,1 
Galβ4GlcNAcβ3Galβ4GlcNAc 
Helicobacter pylori NeuAc(α2–3)Galβ4GlcNAc 
Fucα2Galβ3(Fucα4)Gal 
Klebsiella pneumoniae Man 
Neisseria gonorrhea Galβ4Glc(Nac) 
Neisseria meningitidis [NeuAc(α2–3)]0,1 
Galβ4GlcNAcβ3Galβ4GlcNAc 
Pseudomonas aeruginosa L-Fuc 
Galβ3Glc(Nac)β3Galβ4Glc 
Salmonella Typhimurium Man 
Streptococcus pneumoniae [NeuAc(α2–3)]0,1 
Galβ4GlcNAcβ3Galβ4GlcNAc  
Streptococcus suis Galα4Galβ4Glc 
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Table 3 Inhibition of bacterial pathogens to the surface of epithelial cells in vitro by non-digestible oligosaccharides. 
Non-digestible 
Oligosaccharide 
Cell Line Adherence Inhibition of: References 
HMO Caco-2 Escherichia coli 
Vibrio cholerae 
Salmonella Fyris 
 
(Coppa et al., 2006) 
HMO  Listeria monocytogenes 
 
(Coppa et al., 2003) 
HMO HEp-2 Campylobacter jejuni 
 
(Ruiz-Palacios et al., 2003) 
HMO  Streptococcus pneumoniae 
Haemophilus influenzae 
 
(Andersson et al., 1986) 
HMO HeLa 
HEp-2 
T84  
Enteropathogenic E. coli 
(EPEC) 
 
(Manthey et al., 2014) 
GOS HEp-2 EPEC 
 
(Shoaf et al., 2006) 
GOS HEp-2 Cronobacter sakazakii 
 
(Quintero et al., 2011) 
GOS HT-29 Salmonella enterica serovar 
Typhimurium 
 
(Searle et al., 2009) 
Yeast-derived 
mannoproteins 
 
Caco-2 Campylobacter jejuni (Schoeni and Wong, 1994) 
POS Caco-2 Campylobacter jejuni 
 
(Ganan et al., 2010) 
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CHOS HEp-2 EPEC (Quintero-Villegas et al., 2013) 
 
Glycoprotein 
glycans 
 
Erythrocyte 
glycoconjugates 
E. coli K99 (Mouricout et al., 1990) 
3’sialyllactose HuTu-80 
HEp-2 
Helicobacter pylori (Simon et al., 1997) 
Lacto-N-
neotetraose 
 
Type II lung cell 
line A549 
Streptococcus pneumoniae (Idänpään‐Heikkilä et al., 
1997) 
Lacto-N-
neotetraose 
NeuAcα2-6Galβ1-
4GlcNAc 
GalNAcβ1-
3LacNAc 
 
Chang cells 
 
Streptococcus pneumoniae (Barthelson et al., 1998) 
POS HT29 Enterohemorrhagic E. coli 
(EHEC) O157:H7 Shiga 
toxins 
(Olano-Martin et al., 2003) 
GOS GM1  
(cell surface 
toxin receptor) 
Vibrio cholerae toxin (Sinclair et al., 2009) 
HMO  Clostridium difficile toxins A 
and B (TcdA and TcdB)  
(El-Hawiet et al., 2011) 
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Table 4. Studies of immune modulation by Non-digestible oligosaccharides in vivo 
Non-digestible 
Oligosaccharide 
 
Model Findings References 
GOS  
5000mg GOS/kg 
body weight 
Colitis 
development in 
Smad3-deficient 
mice treated with 
Helicobacter 
hepaticus 
- Colitis severity reduced 
- Increase of NK cells in spleen 
- Increase in MsLN 
- Increased expression of CCR9   in 
blood, spleen and MsLN 
IL-15 production stimulated 
 
(Gopalakrishnan et al., 2012) 
 
FOS  
5% w/w in diet 
2-week- old 
BALB/c mice 
- Increase in intestinal IgA (ileum, 
jejunum, and colon) 
- % of B220+IgA+ cells in Peyer’s 
patches (PP) increased 
 
(Nakamura et al., 2004)  
 
FOS  
10% w/w in diet 
6-week-old female 
BALB/c mice 
(healthy and 
endotoxemic) 
Endotoxemia 
induced by 
lipopolysaccharide 
(LPS) 
intraperitoneally 
 
- FOS increased total immune cell 
yield in both groups 
- B cells were increased in both 
groups  
- T lymphocytes unaltered in healthy 
mice 
- T lymphocytes increased in 
endotoxemic mice 
(Manhart et al., 2003) 
 
 
 
 
 
FOS and/or MOS 
2grs/day 
Adult female Dogs - Ileal IgA increased in dogs fed FOS 
+ MOS 
- Lymphocytes greater in dogs fed 
MOS 
- Serum IgA greater in dogs fed MOS 
 
(Swanson et al., 2002) 
POS  
1-5% (w/w) in diet 
POS + (GOS:FOS) 
(9:1 mixture) 
2% (w/w) in diet 
 
6-week-old female 
C57Bl/6 mice 
Influenza 
Vaccination Model 
- POS enhanced vaccine-specific 
delayed-type hypersensitivity (DTH) 
(dose dependent) 
- Reduction in T-helper 2 (Th2) 
cytokine production in splenocytes 
- POS + (GOS:FOS) was more 
effective in enhancing DTH (Vos et 
al., 2007a) 
 
 
β-1,4 Mannobiose 
(MNB) 
0, 5, 10, or 25 mg/kg 
6-8-week-old 
female BALB/c 
mice (healthy and 
endotoxemic 
mice) 
 
In healthy mice: 
- MNB induced expression of Th1 
and Th2-type cytokines in ileum  
- Increased fecal IgA production 
- Increased splenic NK cell activity 
 
In endotoxemic mice:  
- Reduced expression of TNF-α, IL-6, 
iNOS, and IL-10 
- Increased IL-12p40, IFN-γ, and 
IFN-α expression and NK cell activity 
 
(Kovacs-Nolan et al., 2013) 
Galacto-mannan-
oligosaccharides 
(GMOS) 
0.2% 
15-day-old piglets GMOS and CHOS 
- Enhanced IL-1β gene expression in 
jejunal mucosa and lymph nodes 
- Enhanced serum levels of IL-1β, IL-
(Yin et al., 2008) 
 
 
 
 
CHOS 
250mg/kg 
2, IL-6, IgA, IgG, and IgM 
 
MOS or FOS 
5 g/kg 
Day-old Cobb 
male broilers 
FOS and MOS supplementation 
- Significant reduction in proportion of 
B cells and mitogen responsiveness 
of lymphocytes in cecal tonsils (CT) 
 
FOS 
- Enhanced IgM and IgG in plasma 
 
(Janardhana et al., 2009) 
Goat milk 
oligosaccharides 
(GMO) 
5% (w/w) in diet (20 
g/kg of diet) 
Male Sprague-
Dawley rats 
DSS induced 
inflammation 
GMO supplementation 
- Protected from weight loss  
- Ameliorated acute colonic 
inflammatory process 
- Less severe colonic lesions 
 
(Lara-Villoslada et al., 2006) 
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GOS:FOS (9:1) 
Between 1% and 
10% (w/w) in diet  
 
 
6-8 week old 
C57Bl/6 mice 
Influenza 
Vaccination Model 
DTH response used as a marker of 
Th1 immunity 
- GOS:FOS enhanced DTH response 
in a dose dependent manner 
- No significant differences on 
splenocyte proliferation 
- No significant difference on 
vaccine-specific serum antibody 
concentrations 
 
(Vos et al., 2006) 
GOS:FOS 
1% (w/w) in diet 
 
GOS:FOS (83%) + 
POS (17%) 
1% (w/w) in diet 
5-8 week old 
BALB/c mice 
Mice sensitized with ovalbumin 
(OVA) 
 
GOS:FOS 
- suppressed OVA-induced airway 
inflammation and hyper-
responsiveness 
- OVA specific IgE decreased 
- enhanced Th1 and suppressed Th2 
parameters 
 
GOS:FOS + POS 
- suppressed OVA-induced airway 
inflammation and hyper-
responsiveness 
- OVA specific IgE decreased 
- enhanced Th1 and suppressed Th2 
parameters 
 
(Vos et al., 2007b) 
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CHOS 
100 mg/kg 
intraperitoneally 
(i.p) 
8-10 week old 
BALB/c mice 
LPS-induced 
sepsis 
CHOS treated mice 
- attenuated organ dysfunction 
 -improved survival rate 
- TNF-α and IL-1β reduced in serum 
- neutrophil infiltration in organs 
attenuated 
- protected from redox imbalance 
(attenuated reduction of glutathione 
and catalase and increase of 
malondialdehyde) 
-c-Jun NH2-terminal kinase activation 
attenuated 
- p38 mitogen-activated protein 
kinase signal activation attenuated 
 
(Qiao et al., 2011) 
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Abstract 
Some oligosaccharides are known to act as molecular decoys by inhibiting 
pathogen adherence to epithelial cells.  The present study was aimed at 
analyzing whether chitooligosaccharides (CHOS), i.e. oligomers of D-
glucosamine and N-acetyl-D-glucosamine, have such anti-adherence activity.  
CHOS of varied degree of polymerization (DP) and fraction of acetylation (FA) 
were produced.  Adherence of enteropathogenic Escherichia coli (EPEC) to the 
surface of a human HEp-2 cell line was determined in the absence or presence 
of the various CHOS fractions.  Adherence was assessed by microscopic 
counting and image analysis of bacterial clusters and cells.  The results showed 
that all CHOS fractions inhibited adherence of EPEC to HEp-2 cells.  
Hydrolysates with lower FA were more effective at reducing adherence.  This 
effect is greater than that obtained with other oligosaccharides, such as 
galactooligosaccharides, applied at the same concentrations.  
 
Keywords 
Oligosaccharides, adherence, chitooligosaccharides, chitosan, chitinase, 
chitosanase 
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Introduction 
Oligosaccharides have long been known to have a variety of biological 
activities, although the full diversity of their functions is not yet fully understood1,2. 
In particular, they are known to serve as ligands and participate in  binding 
interactions with specific lectins 2. Recently, it has been suggested that some 
food grade oligosaccharides can protect host tissue from pathogen adherence 3. 
Specifically, galactooligosaccharides (GOS), mannan oligosaccharides, and 
pectic oligosaccharides have been shown to be effective in inhibiting pathogen 
binding to the surface of tissue culture cells4–7. 
For most microbial enteric pathogens, the first step in the infection process 
is adherence to the epithelial cells that line the intestinal tract. Adherence is 
generally mediated in these bacteria via expression of lectin-like adhesins that 
recognize carbohydrate-containing receptor sites on the surfaces of host 
epithelial cells 8,9.   Accordingly, adherence inhibition may occur in the presence 
of substances that interfere with the lectin-receptor interaction, for example, by 
anti-adherence oligosaccharides that resemble the glyco-moieties of the host 
receptor sites.  Thus, strategies based on preventing or inhibiting pathogen 
adherence could be effective at reducing infections and the subsequent onset of 
disease 7,10,11.  
One group of oligosaccharides that has attracted considerable research 
and commercial interest due to their biological properties are the 
chitooligosaccharides (CHOS).  CHOS are produced enzymatically or chemically 
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from chitosan; linear heteropolymers of β (1→4) linked N-acetyl-D-glucosamine 
(GlcNAc) and its deacetylated counterpart D-glucosamine (GlcN).  Chitosans 
may have varying compositions, usually indicated by the fraction of acetylated 
sugar residues (FA). Soluble chitosans are produced from insoluble chitin by 
partial or complete N-deacetylation, either by homogenous 12 or by 
heterogeneous deacetylation 13.  Chitin is an abundant natural product found in 
nature as a structural component of the cell wall of fungi and yeasts and in the 
exoskeletons of insects and arthropods (e.g., crabs, lobsters and shrimps).  
Chitosan has a wide range of applications14–16, including its use as an 
antimicrobial agent17–22. 
Chitosan can be hydrolyzed by chitinases or chitosanases to give CHOS 
23–26.  These hydrolytic enzymes vary with respect to their specific cleavage sites, 
which are determined by sequences in heteropolymers of GlcNAc and GlcN.  
Thus, different combinations of chitosans (varying in FA) and hydrolytic enzymes 
(varying in sequence specificity) will yield CHOS differing in both length and 
sequence features 27.  The resulting CHOS are defined by their FA, their average 
degree of polymerization (DPn) and their sequence, i.e. the pattern of N-
acetylated sugar residues (PA). The DPn is related to α, a parameter that 
indicates the degree of scission, where α = 1/DPn. Complete conversion of 
chitosan to dimers (DPn = 2) would yield an α value of 0.50. Methods exist to 
separate CHOS by DP (e.g, size exclusion chromatography 26) and by charge 
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(e.g., cation exchange chromatography 28). The latter is based on the fraction of 
deacetylated residues.  
CHOS possess a wide range of bioactivities and are used for their anti-
angiogenesis effects, as well as for wound healing and as vectors in gene 
therapy 27,29–32.  Chitosan and CHOS are biodegradable and are considered non-
toxic 33; therefore, these compounds have a variety of potential applications in 
food 34. There is evidence that CHOS (DP < 30, FA 0.01 - 0.12) may be prebiotic, 
enhancing growth of Bifidobacterium and Lactobacillus strains in cell cultures 
35,36.  This effect is apparently dependent on FA, since Fernandes et al. 
37 
reported that CHOS with similar DP but higher FA (FA 0.35) did not stimulate 
growth of selected strains of bifidobacteria and lactobacilli.  
Although pathogen adherence by CHOS has received relatively little 
attention, one previous study showed that a non-defined CHOS mixture of FA0.03 
and DPn ~ 4 inhibited adherence of three different strains of enteropathogenic 
Escherichia coli (EPEC) on HT-29 cells 38.  In additional, Liu et al. showed that 
weaned pigs that were fed CHOS exhibited reduced incidence of diarrhea after 
being challenged with E. coli K88 39.  It is now possible, however, to produce 
more defined CHOS fractions and to assess these fractions for anti-adherence 
activity.  Thus, the main objective of the present study was to test CHOS with 
different FA and DP for their ability to inhibit adherence of EPEC, a widely 
recognized enteric pathogen, on tissue culture cells.  
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Materials and Methods 
 Preparation of CHOS. Three chitosans with different FA were 
enzymatically hydrolyzed.  A chitosan with FA0.15 (KitoNor from Norwegian 
Chitosan, Gardermoen, Norway) and a chitosan with FA0.3 (Heppe Medical 
Chitosan GmbH, Halle, Germany) were hydrolyzed with purified recombinant 
chitosanase ScCsn46A from Streptomyces coelicolor A3(2) 23.  A FA 0.65 
chitosan was prepared by homogenous deacetylation of chitin from shrimp 
shells12 (Chitinor, Senjahopen, Norway). This FA0.65 chitosan was hydrolysed 
with purified recombinant ChiB from Serratia marcescens 26,40. The FA of the 
chitosans before enzymatic hydrolysis, and the degree of scission (α) after 
degradation were determined by 1H-NMR using a Varian Gemini instrument at 
300 MHz 26,41. 
The FA 0.65 chitosan was soluble in water, whereas the FA 0.15 and FA 0.3 
chitosans required 0.5 % acid to dissolve. All three chitosans were 
dissolved/suspended in buffer (40 mM NaAc, 100 mM NaCl, pH 5.5) to a 
concentration of 10 mg/mL.  Then, 0.5 % (v/v) 12 M HCl was added to the FA 
0.15 and FA 0.3 chitosan samples, and after the chitosan was dissolved, the pH 
was adjusted to 5.5 with 6 M NaOH.  Enzymes were added to pre-warmed 
chitosan solutions to a final concentration of 0.5 µg/mg chitosan and the 
reactions, with a final chitosan concentration of approximately 9.8 mg/mL, were 
incubated at 37°C with shaking (225 rpm). Reactions were stopped by 
decreasing the pH to 2.5 with HCl.  The CHOS samples were filtered through 
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Filtropur S 0.2 µm sterile filters (Sarstedt, Germany), lyophilized and 
resuspended in the size exclusion chromatography (SEC) mobile phase to a 
concentration of 20 mg/mL prior to separation on SEC. 
 Separation of CHOS. The CHOS were separated by size exclusion 
chromatography (SEC) on three XK 26 columns packed with SuperdexTM 30 prep 
grade (GE Healthcare) coupled in series with an overall dimension of 2.6 cm × 
180 cm.  The mobile phase (150 mM NH4Ac, pH 4.6) was run at a constant flow 
of 0.8 mL/min 26.  The column eluent was monitored using an RI detector (Gilson 
model 133).  In each run 100 mg of chitosan hydrolysate was applied (i.e. 5 mL) 
and 3.2 mL fractions were collected. Identification of oligomers in the fractions 
was performed with MALDI-TOF-MS.  The fractions were dialyzed with Float-A-
Lyzers (MWCO 100-500 Da, SpectrumLabs) to remove salts, sterile filtrated and 
lyophilized. Prior to use, the CHOS were dissolved in sterile distilled water. 
To limit the number of assays, initial experiments were done with chitosan 
hydrolysates containing mixtures of CHOS.  In this case, dried material was 
resuspended in sterile water to a final volume of 1 mL (final concentration varied 
according to the amount available of each sample).  For other experiments, 
samples were diluted to a final concentration of 16 mg/mL.  
 Strains and Organisms. EPEC strain E2348/69 (O127:H6) was obtained 
from M. Donnenberg (University of Maryland School of Medicine, Baltimore) and 
was used as a model organism for the anti-adherence experiments.  Before each 
experiment, cells from frozen stocks were plated on tryptic soy agar (TSA; Difco, 
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Sparks, USA) and grown overnight at 37°C, as described previously (Shoaf et al., 
2006).   A single colony was then inoculated into 10 mL of tryptic soy broth (TSB; 
Difco) and incubated overnight at 37°C without shaking.  Overnight cultures were 
used to inoculate (1% v/v) minimal essential medium (MEM; Hyclone, Logan, 
USA) supplemented with 10% (v/v) fetal bovine serum (FBS; Hyclone, Logan, 
USA).  MEM was pre-equilibrated overnight at tissue culture conditions (5% CO2, 
95% relative humidity, 37°C).  The cells were then incubated for 80 min at 37°C, 
aerobically, prior to the start of the experiment. 
 Tissue Culture Cells. HEp-2 (CCL-23) cells were obtained from the 
American Type Culture Collection (Manassas, Virginia).  This cell line was used 
to assess bacterial adherence to epithelial cells; they are a widely used cell line 
for studies involving bacterial intestinal adherence 42–44.   HEp-2 cells were grown 
as described previously (Shoaf et al., 2006).  Briefly, cells were grown in 75 cm2 
tissue culture flasks containing 25 mL of MEM (pH 7.4) supplemented with 10% 
FBS in a CO2 incubator at tissue culture conditions.  Confluent HEp-2 cells were 
harvested by removing MEM and washing the cells once with PBS.  
Subsequently, 0.5 mL of a 0.25% Trypsin-EDTA solution was added followed by 
a 10 minute incubation at tissue culture conditions. After incubation, 0.5 mL of 
FBS was added to inactivate the trypsin.  Cells were then seeded onto 12 mm 
diameter glass coverslips in 24-well tissue culture plates at approximately 3.6 × 
105 cells per well, and 500 μl of MEM supplemented with 10% FBS was added to 
each well.  Plates were incubated under tissue culture conditions for about 20 
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hours prior to the start of each experiment.  Cells were checked before the 
experiment under an inverted microscope to make sure they had reached about 
70% confluency. 
 Anti-adherence Assays. CHOS were dissolved in sterile water and 
mixed with bacterial cultures (approx. 108 cells/mL in MEM supplemented with 
10% FBS) to final concentrations of 16 mg/mL, prior to addition to the tissue 
culture cells.  A total of 14 fractions were analyzed - three CHOS mixtures 
resulting from enzymatic hydrolysis of three different chitosans (FA 0.15, FA 0.3, 
and FA 0.65) and 11 fractions derived from hydrolyzed FA 0.15 chitosan by size 
exclusion.  In addition, a mixture of N-acetyl-D-glucosamine (Sigma) and D-
glucosamine (Sigma) (15:85) was used as a control.  It was not possible to test 
the non-hydrolyzed chitosans, due to the viscous nature of the chitosan 
solutions.  Sterile water was also used as a control.  The standard CHOS 
concentration of 16 mg/mL was used because previous experiments with GOS 
had shown this concentration to be effective in inhibiting adherence of EPEC 7.  
However, for some of the fractions the amount of material was limited, and the 
concentration used was significantly lower. In addition, dose responses of the 
fractions FA 0.15 and FA 0.3 were performed to determine the effect of 
concentration on adherence inhibition.  
After addition of the bacteria/CHOS mixtures to tissue culture cells, the 
plates were incubated for 30 minutes at tissue culture conditions (as described 
above).  The wells were then washed five times with PBS to remove non-
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adhered bacteria.  Cells were then fixed with 100% methanol and stained with 
10% Geimsa. Glass coverslips with stained cells were mounted on microscope 
slides and analyzed by phase contrast microscopy (100x) with an attached 
camera.  A predetermined horizontal and vertical pattern was established to 
obtain fifteen images of each cover slip.   Bacterial clusters (defined as bundles 
of 4 or more bacteria) and HEp-2 cells were counted using ImageJ software to 
obtain a ratio of bacterial clusters/100 HEp-2 cells.  Single concentration 
experiments were replicated once (n=2) and dose responses were replicated five 
times (n=5).   The % inhibition was calculated as the number of adhered clusters 
in the control minus the number of adhered clusters in the treatment, all divided 
by the number of adhered clusters in the control.  Thus, 0% inhibition would refer 
to the control containing only water. Because EPEC cluster formation occurs via 
bundles of 4 or more bacteria, microscopy is the preferred method for quantifying 
adherence of this organism.  It is also used to assess the manner of cell 
attachment of other bacteria 7,45.  
 
Results  
 Production, separation and characterization of CHOS. In the initial 
experiments, chitosans with FA 0.15 and FA 0.3 were enzymatically hydrolyzed 
with chitosanase SnCsn46A from Streptomyces coelicolor A3(2) to α = 0.22 and 
0.25, respectively (corresponding to DPn values of 4.5 and 4.0, respectively).  
The FA 0.65 chitosan was enzymatically hydrolysed by ChiB from Serratia 
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marcescens to α = 0.19 (DPn 5.3).  The α values were determined by 
1H-NMR as 
described previously 31 and SEC chromatograms of the samples (not shown) 
confirmed that, as expected, the majority of the CHOS was in the DP 2 - 20 
range.  
Since the FA 0.15 sample was the most inhibitory in the initial experiments 
(see below), a new hydrolysis reaction was set up (α = 0.16, DPn 6.3) and the 
CHOS were separated into single fractions (DP 3 – DP12) and one fraction with 
DP > 12 and a DPn of 25 (Figure 1A).  The MALDI-TOF-MS spectra of the 
individual DP3 - DP12 fractions demonstrate that the various fractions were 
generally homogeneous with respect to DP (Figure 1B and 1C).  The mass 
spectra also give an impression of the FA distributions within the samples.  For 
example, the DP4 fraction contains primarily D4 and D3A1, the DP6 fraction 
contains D6, D5A1 and D4A2, and the DP12 fraction contains D12, D11A1, D10A2, 
D9A3 and D8A4. 
 Inhibition of EPEC adherence by CHOS mixtures with FA 0.15, FA 0.3 
and FA 0.65. The non-separated hydrolysates of chitosans with FA 0.15, FA 0.3 
and FA 0.65, were tested for their ability to inhibit EPEC adherence at a 
concentration of 16 mg/mL, a concentration used in previous studies for other 
prebiotic oligosaccharides 7,45.  In addition, the adherence inhibition activity of 
fractions FA 0.15 and FA 0.3 was also assessed over a range of concentrations 
(0, 0.5, 1, 5, 10, and 16 mg/mL).  Microscopic analysis revealed that EPEC 
adherence was reduced by the FA 0.15 fraction (Figure 2), and by image 
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analysis, all three hydrolysates significantly inhibited adherence (Figure 3C). For 
both fractions FA 0.15 and FA 0.3, a dose- dependent trend was observed (Figure 
3A and 3B).  Comparison of CHOS based on FA revealed that the FA 0.15 fraction 
gave the highest inhibition (92%) as compared to the FA 0.65 sample (75%) and 
the FA 0.3 sample (84%).  It was not possible, however, to assess the activity of 
non-hydrolyzed chitosans because the high viscosity of the chitosan solutions 
interfered with adherence experiments.  Bacterial motility is reduced in highly 
viscous solutions, resulting in obstruction of bacteria from coming in contact with 
the tissue culture cells. 
 Inhibition of EPEC adherence by purified CHOS fractions. Single 
fractions of CHOS purified from hydrolyzed FA 0.15 chitosan as described above 
(Figure 1) were then tested in the same EPEC adherence assay.  The fractions 
tested were single fractions of DP3 to DP12, and a mixture with DP>12 and DPn 
= 25.  All CHOS fractions significantly inhibited adherence compared to the 
control, reaching inhibition levels of close to 100% (Figure 4).  Notably, 
adherence was not inhibited by addition of a 15:85 mixture of the monomers, 
GlcNAc and GlcN (DP1 in Figure 4), indicating that the oligomeric nature of the 
sugars is essential for the inhibitory effect.  
 Growth of EPEC in the presence of CHOS, GlcNAc and GlcN.  EPEC 
was grown in TSB medium containing monomers of GlcNAc, GlcN, and a 15:85 
mixture of these sugars, all at a concentration of 16 mg/mL (i.e. the same 
concentration used in the CHOS anti-adherence assays).  Growth of EPEC was 
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not impaired by the presence of any of these monomers or the mixture (Figure 
5).  A similar experiment with one of the CHOS fractions also showed that growth 
of EPEC was unaffected by CHOS in the media.  In addition, the bacterial 
inoculum was enumerated before and after incubation to assure there was no 
reduction due to a potential bactericidal effect of the CHOS (data not shown).  
Discussion 
 The use of molecular decoys as anti-adherence agents was proposed 
more than a decade ago 8,46–48.  In recent years, several food grade prebiotic 
oligosaccharides and plant extracts have been tested for their ability to inhibit 
pathogen adherence to the surface of intestinal epithelial cells.  In a previous 
study, we showed that GOS inhibited EPEC adherence by up to 65% under 
conditions similar to those used in the present study 7.  Interestingly, the results 
indicate that CHOS, especially those with low FA, are more effective inhibitors of 
EPEC adherence than GOS, given that inhibition reached almost 100% for some 
of the fractions tested.  
Our results also showed that chitooligosaccharides with different FA, but 
similar DPn (4.0 – 5.3) had comparable adherence inhibition activities, with low FA 
being the most effective (Figure 3C).  Thus, the glucosamine content, which 
affects charge density due to the titratable amino group of this sugar, appears to 
affect the activity of CHOS against EPEC adherence.  Furthermore, a dose-
dependent anti-adherence effect was observed, as greater adherence inhibition 
occurred at the higher concentrations, until a plateau was reached.  In addition, 
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the results showed that hydrolysates with different FA require different 
concentrations to reach the same level of inhibition (Figure 3A and 3B).  
Adherence inhibition, however, did not appear to be related to DP, as CHOS 
fractions purified from a hydrolyzed FA 0.15 chitosan, but with DP’s ranging from 
3 to greater than 12, all inhibited adherence by up to 99%.  Nevertheless, it 
should be noted that CHOS with different DPs will have different molecular 
weights, hence contributing a different number of target molecules despite being 
used at the same concentration. 
The anti-adherence property of oligosaccharides has been attributed to 
the similarity between the oligosaccharide structure and cell surface receptor to 
which bacteria attach prior to colonization.  Via a phenomenon known as phase 
variation 49, bacteria can modulate adhesin expression, depending, in part, on the 
available receptors expressed by the host cells.  This may account for why some 
oligosaccharides are effective in inhibiting adherence of particular pathogens 
whereas other pathogens are not affected.  Moreover, the molecular interaction 
between oligosaccharides and bacterial adhesins varies among different 
pathogens, and in some cases among different strains 7,45. 
Recently, it was suggested that pathogen adherence tropism is dependent 
on three key elements: expression of adhesins; adhesion specificity; and the 
presence of cognate receptors on the surface of specific tissue culture cells 50.  
Although the precise mechanism for how CHOS prevent adherence of EPEC to 
epithelial cells will require further investigation, we suggest that CHOS interferes 
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with adhesion attachment to the cognate ligands.  In particular, one of the 
monomers of CHOS is GlcNAc, which is a common constituent of receptor 
ligands for many bacterial lectins 51–53.  However, the occurrence of non-
acetylated glucosamines as a target ligand on the surface of epithelial cells has 
not been reported.  In addition, the present data clearly shows that inhibition of 
adherence requires an oligomeric carbohydrate (Figure 4), as free monomeric 
sugars had no effect on adherence. 
The ability of chitosan polymers to inhibit growth of E. coli has been 
reported previously19,54,55, although this effect was observed only for chitosans of 
higher DP than that of the CHOS used in the present study. Other studies have 
shown that shorter CHOS, at DP < 20 do not kill E. coli 20,55.  Indeed, growth of 
EPEC was not impaired by the CHOS used in this study, indicating that reduced 
adherence of EPEC was not due to growth inhibition or cell killing.  Thus, it 
seems that the anti-adherence effect of CHOS is independent of the other 
biological effects of CHOS and chitosan.  
 In summary, our results show that different fractions of CHOS inhibit 
adherence of EPEC to the surface of tissue culture cells.  Further research is 
needed to identify the specific CHOS species responsible for the observed 
inhibition and to assess these effects in vivo, i.e., on pathogen adherence in the 
animal gastrointestinal tract.  Finally, other potential biological activities of CHOS, 
including their possible impact on the intestinal commensal microbiota, should 
also be considered.  Certainly, non-pathogenic strains of E. coli may also 
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express adhesins and bind to CHOS or other molecular decoys.  However, 
provided the concentration of the anti-adherence agents is sufficient, inhibition of 
targeted pathogens would still be expected to occur. 
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Figure 1. SEC and MALDI-TOF analysis of hydrolyzed FA0.15 chitosan. Size 
exclusion chromatogram (SEC) of CHOS obtained by enzymatic hydrolysis of the 
FA0.15 chitosan with ScCsn46A from Streptomyces coelicolor A3(2) (A). Peaks 
are labeled by the DP of the oligomers they contain; the region labeled “>12” and 
“DPn25” was collected and tested as one (mixed) fraction.  MALDI-TOF-MS 
analysis was performed on the different SEC fractions.  The DP 3-7 fractions (B) 
and DP 8-12 fractions (C) are shown.  Major signals are labeled by mass, sugar 
composition (A, GlcNAc; D, GlcN) and adduct type (H+, Na+ or K+). 
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Figure 2.  Micrographs (100X magnification) of EPEC adherence to HEp-2 cells 
in the absence (A) and presence (B) of CHOS with FA 0.15 at a concentration of 
16 mg/ml. 
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Figure 3. Inhibition of EPEC adherence to HEp-2 cells by CHOS mixtures 
with different FA.  The % Inhibition was calculated as described in the text.  
Statistical analysis was performed by Analysis of Variance (ANOVA) to 
determine statistical differences from the control, and Tukey’s test was used to 
determine significant differences among the treatments.  Values sharing the 
same letter are not significantly different from each other (p < 0.05)  For FA 0.15 
and FA 0.3 dose experiments (A and B, respectively), n = 5; for comparison 
between  FA 0.15, FA 0.3, and FA 0.65 (C), n = 2 
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Figure 4. Inhibition of EPEC adherence to HEp-2 cells by purified CHOS 
fractions with different DP.  Statistical analysis was performed by Analysis of 
Variance (ANOVA) to determine statistical differences from the control, and 
Tukey’s test was used to determine significant differences among the treatments 
(n = 2).  Groups sharing the same letter are not significantly different from each 
other (p < 0.05). 
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Figure 5. Growth of EPEC in the presence and absence of GlcN and 
GlcNAc.  Growth of EPEC in TSB at 37°C was measured in the absence () or in 
the presence of added sugars. Sugars tested were GlcN (), GlcNAc () and a 
85:15 mix of GlcN: GlcNAc (), all at a total sugar concentration of 16 mg/ml. 
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Abstract 
Cronobacter sakazakii is now recognized as an opportunistic pathogen and has 
been implicated in rare but severe cases of necrotizing enterocolitis, meningitis, 
and sepsis in neonates. The first step in bacterial pathogenesis requires that the 
organism adhere to host cells surfaces; therefore, agents that inhibit adherence 
might be useful for preventing infections. Lactoferrin, an iron binding protein 
found in milk, has been shown to inhibit bacterial adherence by direct interaction 
and disruption of bacterial surfaces. Therefore, the goal of this research was to 
assess the ability of two different types of bovine lactoferrin, alone and in 
combination with a 1:1 blend of galactooligosaccharides and polydextrose, to 
inhibit adherence of Cronobacter sakazakii to a HEp-2 human cell line. Results 
showed that the adherence of C. sakazakii was significantly reduced at a 
minimum lactoferrin concentration of 10 mg/ml.  However, in combination with 
the oligosaccharide blend, no synergistic effect was observed in adherence 
inhibition. These results suggest that lactoferrin might interact with C. sakazakii 
and directly inhibit adhesion to tissue culture cells. 
 
Key Words: Lactoferrin, Galactooligosaccharides, Polydextrose, Antiadherence 
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Background 
Cronobacter sakazakii is now considered an opportunistic pathogen that 
has been implicated in bacteremia, necrotizing enterocolitis, and neonatal 
meningitis [19].  Although C. sakazakii infections are more common in neonates 
and premature babies, it has been reported that immune compromised adults are 
also susceptible to infections caused by this bacterium [19]. The infant mortality 
rate associated with C. sakazakii infections ranges from 40 to 80% [7]. In 
addition, survivors often develop serious long-term neurological complications 
[26]. The bacterium has been isolated from a range of food sources including 
dairy-based foods, dried meats, water, and rice [6, 44]. In particular, powdered 
infant formula has been epidemiologically linked with many of the infections 
reported [54]. Despite the relatively low incidence of disease, the severity of 
these diseases has led to considerable interest in developing strategies for 
preventing or mitigating infections.   
Lactoferrin (Lf) is an 80 kDa iron binding glycoprotein, belonging to the 
transferrin family. It is found in high concentrations, up to 10 mg/ml in human 
colostrum [1] and up to 1.5 mg/ml in bovine colostrum [55]. The concentration of 
Lf in mature milk varies over time and is dependent on the stage of lactation [14]. 
Several biological functions have been attributed to Lf [30]. It has been 
reported to have bactericidal and bacteriostatic properties, as well as anti-
inflammatory and immunomodulatory activities, based on both in vitro and in vivo 
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models [16]. In particular, Lf is known for its antimicrobial activity, for which at 
least two different mechanisms have been proposed. The first model is based on 
the ability of Lf to sequester iron, depriving pathogens from this essential nutrient 
and inhibiting their growth [14, 21]. This antimicrobial activity is reduced upon 
iron saturation of the molecule, suggesting that Lf is bacteriostatic rather than 
bactericidal [4, 14, 22, 50, 53]. A second means by which Lf exhibits antimicrobial 
activity is via an iron-independent mechanism.  According to this model, Lf 
inhibits bacterial pathogens by a direct interaction mediated by binding of the 
Lipid A portion of the lipopolysaccharide (LPS) of Gram negative bacteria [2, 8, 
43].  
 There is now evidence that Lf can also inhibit bacterial adherence to host 
cell surfaces - the first step for bacterial pathogenesis. Lf isolated from human 
milk was reported to inhibit adherence of enteropathogenic Escherichia coli 
(EPEC) to HeLa cells [3]. Similarly, bovine Lf was shown to significantly decrease 
adherence of enteroaggregative E. coli (EAEC) to HEp-2 cells and 
enterotoxigenic E. coli (ETEC) adherence to JTC-17 cells [23, 32]. In addition, it 
was reported that Lf inhibits adherence of E. coli O157:H7 to Caco-2 cells in a 
dose dependent manner, mainly due to disruption of the Type III Secretory 
System [55]. Other studies have shown that human Lf has proteolytic activity,  
providing an additional mechanism by which it can exhibit anti-adherent activity 
[38, 50].  
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It was previously reported that galactooligosaccharides (GOS) have an 
inhibitory effect on the adherence of C. sakazakii to intestinal-derived cells in 
tissue culture experiments [40]. In addition, polydextrose (PDX), an 
oligosaccharide chemically synthesized from glucose, exhibited anti-adherence 
activity, but to a somewhat lesser extent [39].  The main goal of this study was to 
assess the ability of bovine Lf, alone and in combination with a prebiotic blend of 
GOS and PDX, to inhibit C. sakazakii adherence. EPEC was used as a positive 
control, as it has been previously reported that Lf inhibits EPEC adherence to 
epithelial cells [3].  
Materials and Methods 
Organisms and growth conditions.  
C. sakazakii 4603 (milk powder – infant formula isolate) used in this study was 
obtained from K. Venkitanarayanan (Department of Animal Science, University of 
Connecticut) and conditions for its growth have been previously described [39].  
Briefly, frozen stock cultures of the organism were thawed, plated onto Tryptic 
Soy Agar (TSA; Difco) and grown overnight at 37°C.  A single colony was 
inoculated into 10 ml of Tryptic Soy Broth (TSB; Difco) and incubated aerobically, 
without shaking. A 1% inoculum was transferred to fresh TSB media and 
incubated for 4 hours at 37°C without shaking. Cultures were harvested by 
centrifugation (3,184 x g for 8 minutes), washed once with phosphate-buffered 
saline (PBS) and re-suspended in minimal essential medium (MEM; Hyclone, 
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Logan, Utah), supplemented with 10% fetal bovine serum (FBS; Hyclone). 
Minimal essential medium was pre-equilibrated at tissue culture conditions (5% 
CO2, 95% relative humidity, 37°C).   
EPEC strain E2348/69 (O127:H6) was obtained from M. Donnenberg (University 
of Maryland School of Medicine, Baltimore). Before each experiment, frozen 
stock cultures were plated onto TSA and grown overnight at 37°C. A single 
colony was inoculated into 10 ml of TSB and incubated overnight at 37°C without 
shaking. Overnight cultures were then inoculated at 1% (vol/vol) into MEM 
supplemented with 10% FBS that was pre-equilibrated at tissue culture 
conditions. Cells were then incubated in MEM for 80 min at 37°C prior to the start 
of the experiment. 
Lactoferrin.  Two different types of bovine Lf were used in these experiments.  
Lf-A was a spray-dried product from FrieslandCampina Domo (Amersfoort, 
Netherlands) and Lf-B was a freeze-dried product from Fonterra (New Zealand).  
Purity (> 90%) and iron saturation levels were similar for both products.  Both Lf 
were prepared as concentrated stock solutions with distilled sterile water to give 
a final concentration of 100 mg/ml.  The solutions were filter sterilized using 0.22 
µm membrane filters.  
Tissue culture cells.  HEp-2 cells, a widely-used cell-line for adherence 
experiments, were obtained from the American Type Culture Collection (ATCC; 
Manassas, Virginia).  Cells were grown in 75 cm2 tissue culture flasks (Corning) 
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containing 25 ml of MEM supplemented with 10% FBS in a CO2 incubator at 
tissue culture conditions.  Confluent Hep-2 cells were harvested by adding 0.5 ml 
of 0.25% Trypsin-EDTA Solution (Sigma) and incubating for 15 minutes at tissue 
culture conditions.  Trypsin was inactivated with 0.5 ml of FBS. Cells were then 
seeded onto 12-mm diameter glass coverslips in 24-well tissue culture plates 
(Falcon) at approximately 3.6 x 105 viable cells per well, and 500 µl of MEM 
supplemented with 10% FBS was added to each well.  Plates were incubated 
under tissue culture conditions 30 hours prior to the start of each experiment, or 
until confluency was reached. 
Adherence Assays. Cell suspensions of C. sakazakii 4603 and EPEC were 
prepared as described above.  Lf was mixed with bacterial cultures at a 
concentration of 108 CFU/ml (in MEM supplemented with FBS) prior to addition to 
the tissue culture cells. The plates were incubated for 30 minutes at tissue 
culture conditions. Preliminary experiments indicated that 30 minutes of 
incubation were optimal for adherence of the bacterial strains to the HEp-2 tissue 
culture.  Assays were done in duplicate and replicated 3 times (n=6). ANOVA 
with Tukey’s test was used for statistical analysis using GraphPad Prism5 
software.  
Quantitative PCR (qPCR). qPCR was used for enumeration of adhered C. 
sakazakii 4603 cells. Bacterial cells from adherence assays were detached by 
the addition of 1 ml of 0.1% Triton X-100 for 30 minutes at room temperature. 
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Bacterial cells were harvested and centrifuged for 5 min at 10,000 x g, 
supernatants were discarded, and pellets were resuspended in 180 µl of buffer 
ATL from the DNeasy Blood and Tissue Kit (Qiagen, Hilden, Germany).  
Instructions provided in the manufacturer’s manual for DNA extraction of Gram 
negative bacteria were followed.  
Species-specific primers described by Liu et al. [29] (forward primer: 5’- 
TATAGGTTGTCTGCGAAAGCG – 3’; reverse primer: 5’- 
GTCTTCGTGCTGCGAGTTTG – 3’) were used. A standard curve was prepared 
from overnight C. sakazakii 4603 cultures with known cell counts. DNA was 
extracted as previously described. The qPCR was run using a Mastercycler 
Realplex2 (Eppendorf AG, Hamburg, Germany). Each PCR was done in a 25 µl 
volume. The reaction mixture comprised 11.25 µl of the 20x SYBR solution and 
2.5-µl Real-MasterMix (5Prime), 0.5 µM of each primer, and 1µl of DNA template 
[31]. The program used consisted in an initial denaturation at 95°C for 10s, and 
45 cycles of denaturation at  95°C for 5s and 62°C for 20s for annealing and 
extension. Detection limit was determined by running DNA samples of known C. 
sakazakii 4603 concentration.  
Results 
Lf-A and Lf-B, alone and in combination with a mix of GOS-PDX, inhibit 
adherence of C. sakazakii to HEp-2 cells.  
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Adherence assays were performed with C. sakazakii on a HEp-2 cell line. Strain 
4603 has been previously reported to be a suitable model for anti-adherence 
experiments [39], and was used for all experiments in this study. Adherence of C. 
sakazakii to HEp-2 cells in the presence and absence of Lf by itself or in 
combination with GOS-PDX was measured by qPCR. Initial Lf doses used 
ranged from 0.1 to 1.0 mg/ml, however, no inhibition was observed at these 
concentrations (data not shown). Subsequently, adherence of C. sakazakii 4603 
in the presence of Lf-A and Lf-B, in doses ranging from 2 to 50 mg/ml, was 
assessed. Adherence inhibition (80 – 99%) was observed at a minimum 
concentration of 10 mg/ml of Lf-A and Lf-B, respectively.  Higher concentrations, 
however, did not show any additional significant anti-adhesive effects (data not 
shown). Lf was used at a concentration of 10 mg/ml for all subsequent anti-
adherence assays with C. sakazakii.   
Next, adherence of C. sakazakii 4603 was measured in the presence of Lf, in 
combination with a mixture of GOS-PDX (16 mg/ml).  However, no additional 
adherence inhibition was observed in the treatment samples that contained Lf 
and GOS-PDX, indicating there was not a synergistic or additive effect when 
combining these agents (Fig. 1).   
Lf-A and Lf-B, alone and in combination with a mix of GOS-PDX, inhibit 
adherence of EPEC to HEp-2 cells.  
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EPEC adherence was measured in the presence and absence of Lf-A and Lf-B, 
alone and in combination with a mix of GOS-PDX, by qPCR. First, EPEC 
adherence was assessed in the presence and absence of Lf-A and Lf-B at 
concentrations ranging from 2 to 50 mg/ml. The results indicated that a minimum 
Lf-A and Lf-B concentration of 10 mg/ml was required to inhibit adherence of 
EPEC to HEp-2 cells. However, as Lf-A and Lf-B concentrations increased, 
higher adherence inhibition was observed, suggesting that the effect on EPEC 
adherence varies in a dose dependent manner (data not shown).  Subsequently, 
EPEC adherence was assessed in the presence and absence of Lf-A and Lf-B at 
a concentration of 10 mg/ml, alone and in combination with a mix of GOS-PDX at 
a concentration of 16 mg/ml.  Lf-A and Lf-B inhibited adherence of EPEC to HEp-
2 cells, alone and in combination with GOS-PDX.  However, as for C. sakazakii, 
no significant increase in adherence inhibition was observed when both 
treatments were combined. This suggests that there is no synergistic effect by 
combining both treatments (Fig. 2).  
Lf-A and Lf-B do not impair growth of C. sakazakii 4603. 
C. sakazakii 4603 was grown in TSB containing Lf-A or Lf-B at a concentration of 
10 mg/ml (i.e. the same concentration used in the anti-adherence assays) (Fig. 
3). Growth of C. sakazakii 4603 was not impaired by the presence of Lf-A and Lf-
B in the growth medium, suggesting that the reduction in adherence was not due 
to a bactericidal effect against C. sakazakii. Additionally, Lf had no effect on 
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growth of EPEC, indicating that reduction of adherence was not due to a 
bactericidal effect (data not shown).  
Moreover, C. sakazakii 4603 and EPEC were grown in TSB containing Lf-A or Lf-
B (10 mg/ml) combined with GOS-PDX (16 mg/ml). Growth was not impaired by 
the presence of Lf-A and Lf-B combined with GOS-PDX in the growth medium 
(data not shown). 
Discussion 
Preventing pathogen adherence to host cell surfaces has been recognized 
as a novel approach to prevent or mitigate bacterial infections [11, 46, 47]. 
Adherence to host cell surfaces requires recognition of specific host cell 
receptors by the bacterial pathogen, and it is the first, and one of the main, steps 
in bacterial pathogenesis [36]. This interaction can be mediated by different 
mechanisms including bacterial lectins and host glycoproteins, bacterial lectins 
and host glycolipids, bacterial lipopolysaccharide and host lectins, hydrophobin – 
protein interactions, and protein – protein interactions [36]. Compounds with 
similar structures to those found in the surface of cells may act as molecular 
decoys that interfere with the different mechanisms of pathogen binding [45, 46, 
49]. Among these compounds, non-digestible oligosaccharides, such as GOS, 
have been shown to inhibit pathogen adherence to epithelial cells in vitro and in 
vivo [24, 32, 33]. Other compounds, such as bovine Lf, have attracted much 
attention for their biological properties, including anti-adherence.  
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Among the biological functions attributed to Lf are antimicrobial, anti-
inflammatory, and immunomodulatory activities [1, 9, 25, 27, 52]. The 
mechanisms that account for the antimicrobial properties have been reported to 
be iron-dependent and iron-independent [4, 10, 12, 37]; the latter implying direct 
interaction of Lf with the bacterial cell surface [2, 8, 43]. This direct interaction 
can result in the inability of the bacterium to adhere to host cell surfaces [13, 18, 
21, 34, 38]. Previous studies have shown that Lf prevents colonization of 
Haemophilus influenzae, degrades virulence proteins secreted by Shigella 
flexeneri, and inhibits adherence of Salmonella Typhimurium. In addition,  Lf has 
been shown to interfere with the Type III Secretory System present in many 
pathogenic bacteria [5, 13, 16–18, 21, 34, 38].  
This is the first study that provides evidence that Lf inhibits adherence of 
C. sakazakii to human epithelial cells in vitro. Our results show that two different 
types of Lf inhibited adherence of C. sakazakii and EPEC, alone and in 
combination with a mix of GOS-PDX.  It was previously reported that a mix of 
GOS-PDX inhibits adherence of C. sakazakii to HEp-2 cells at a concentration of 
16 mg/ml [39].  However, no synergistic effect was observed when using this 
same prebiotic blend in combination with Lf. Despite lacking a synergistic effect, 
Lf was shown to inhibit adherence of C. sakazakii at a minimum concentration of 
10 mg/ml.  Interestingly, the minimal effective concentration of Lf to inhibit 
adherence of C. sakazakii and EPEC corresponds to the Lf levels found in 
human colostrum [40, 41].  At this same concentration (10 mg/ml), neither of the 
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lactoferrins were able to inhibit growth of C. sakazakii (Fig. 3), nor was a 
bactericidal effect evident when EPEC was incubated in the presence of Lf.  In 
contrast, Wakabayashi et al. [51] reported that bovine lactoferrin exhibited 
antimicrobial activity against C. sakazakii and E. coli. 
The antimicrobial effect of native, partially hydrolyzed, and heated 
lactoferrin has been well studied. Although iron sequestration may contribute, in 
part, to microbial inhibition, especially in low iron environments, other factors are 
likely involved [21]. In particular, it has also been shown that the positively 
charged N-terminal regions of lactoferrin interact with the lipid A component of 
the bacterial membrane, resulting in membrane disruption [2, 15]. However, other 
studies have shown no antimicrobial effect of bovine Lf on EPEC. For example, 
Ochoa et al. [33, 34] did not observe any bactericidal effect when EPEC was 
grown in DMEM in the presence of bovine Lf. In addition, the ability of Lf to 
degrade EPEC virulence proteins has been reported, independent from any 
bactericidal effect [35]. 
 The pathogenesis of C. sakazakii, its mode of adherence to host cell 
surfaces and expression of adhesins have not been well studied, although it has 
been established that an outer membrane protein A (OmpA) might play an 
important role in the attachment and invasion of Caco-2 cells [24]. Following cell 
attachment, human isolates of C. sakazakii have been shown to disrupt cell tight 
junctions and increase enterocyte permeability [28]. The mechanism by which Lf 
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inhibits adherence of C. sakazakii will require further investigation.  For E. coli 
O157:H7, Lf-mediated adherence inhibition to Caco-2 cells was suggested to be 
due, in part, to disruption of the Type III Secretory System [55].  However, it is 
not clear that this effect is strictly dependent on the direct interaction of the 
protein with the bacterial cell surface. 
Collectively, these results show that Lf-A and Lf-B, at a concentration of 
10 mg/ml, inhibit adherence of C. sakazakii 4603 and EPEC to HEp-2 cells. 
However, a synergistic effect was not observed when combining Lf with a mixture 
of GOS-PDX. Novel ingredients that are able to prevent binding of pathogens to 
the surface of cells have attracted great interest, as they have the potential to be 
used as prophylactic treatments to prevent or mitigate infections.  Preventative 
approaches are especially warranted in the case of Cronobacter-induced 
diseases, due to the high mortality and limited post-infection therapies [20]. 
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Fig. 1 Lf-A and Lf-B, in combination with 16 mg/ml GOS-PDX, inhibit 
adherence of C. sakazakii to HEp-2 cells 
Adherence of C. sakazakii in the presence and absence of Lf-A and Lf-B and a 
GOS-PDX mix was measured by qPCR. Adherence inhibition was observed at a 
concentration of 10 mg/ml Lf combined with 16 mg/ml PDX-GOS. Groups 
significantly different from the control are indicated by an *. Groups with different 
letters are significantly different from each other (α < 0.05). 
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Fig. 2 Lf-A and Lf-B, in combination with 16 mg/ml GOS-PDX, inhibit 
adherence of EPEC to HEp-2 cells 
Adherence of EPEC in the presence and absence of Lf-A and Lf-B and a GOS-
PDX mix was measured by qPCR. Adherence inhibition was observed at a 
concentration of 10 mg/ml Lf combined with 16mg/ml PDX-GOS. There is not a 
synergistic effect observed when combining both treatments. Groups significantly 
different from the control are indicated by an *. Groups with different letters are 
significantly different from each other (α < 0.05). 
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Fig. 3 Growth of C. sakazakii 4603 in the presence and absence of Lf-A and 
Lf-B 
Growth of C. sakazakii 4603 in TSB at 37°C was measured in the presence (■, 
▲) or absence (●) of added Lf. Total Lf concentration tested was 10mg/ml. 
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Chapter 4 
Impact of Galactooligosaccharide Supplementation on Susceptibility to 
Enteric Bacterial Pathogens  
 
125 
 
 
 
Abstract 
In addition to their ability to modulate the gastrointestinal microbiota, some 
prebiotic oligosaccharides have other biological properties.  Specifically, 
galactooligosaccharides (GOS) and other prebiotics have also been shown to 
inhibit adherence of pathogens to the surface of epithelial cells.  In this study, 
GOS was tested for the ability to reduce adherence of Citrobacter rodentium to 
the surface of epithelial cells in vitro, on a HEp-2 tissue culture cell line, and in 
vivo, in conventional flora and germ free C57Bl/6 mice. C. rodentium is an 
attaching and effacing (A/E) mouse pathogen used as a surrogate model to study 
enteropathogenic Escherichia coli (EPEC) and enterohemorragic E. coli (EHEC) 
in mice, and was used as the model organism. For the in vitroexperiments, HEp-
2 cells were incubated with C. rodentium DBS100Nalr with and without GOS (10 - 
50 mg/ml). Bacterial adherence was quantified by serial dilutions and plating. For 
in vivo experiments, germ free and conventional flora mice were supplemented 
with GOS for two weeks prior to inoculation with C. rodentium DBS100Nalr.  
Bacterial adherence to the distal colon was quantified by plating and 
histopathology was performed to assess the severity of the lesions. Results 
indicated that GOS reduced adherence of C. rodentium DBS100Nalr in vitro on 
HEp-2 cells. When mice were supplemented with GOS at a concentration of 
5000 mg/kg of body weight, adherence of C. rodentium to the mouse distal colon 
was reduced in conventional flora mice but not in germ free mice. Histological 
scores in conventional flora mice indicated profound lesions in the mice infected 
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with C. rodentium, and no significant difference was observed in the GOS 
supplemented group as compared to the infected control.  
 
Key Words: galactooligosaccharides, antiadherence, Citrobacter rodentium, 
conventional flora mice, germ free mice.  
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Introduction 
Prebiotic oligosaccharides are currently defined as selectively fermented 
ingredients that allow specific changes, both in the composition and/or activity in 
the gastrointestinal microbiota, that confer benefits upon host well-being and 
health (Roberfroid, 2007).  Although this definition has evolved since it was first 
stated nearly 20 years ago (Gibson and Roberfroid, 1995), to be considered as a 
prebiotic the substance must still be able to modulate the gut microbiota. Among 
the specific colonic microbial species that selectively ferment prebiotic 
oligosaccharides are members of the genus Bifidobacterium.  These colonic 
bacteria ferment prebiotic substrates and produce short chain fatty acids (SCFA) 
that are beneficial to the host (Nicholson et al., 2012; Wong et al., 2006) and 
inhibitory against opportunistic pathogens (Defoirdt et al., 2006; Van Immerseel, 
2003; Tejero-Sariñena et al., 2012).  
In addition to their role as fermentation substrates, some prebiotic 
oligosaccharides have been shown to possess another important biological 
activity.  Specifically, they can act as molecular decoys that competitively inhibit 
adherence of pathogens to host cells (Quintero et al., 2011; Quintero-Villegas et 
al., 2013; Shoaf et al., 2006; Shoaf-Sweeney and Hutkins, 2008).  This 
adherence inhibition property is due to the structural similarity between prebiotic 
oligosaccharides and the carbohydrate moieties located on the surface of 
epithelial cells.  For many enteric pathogens, these surface carbohydrates serve 
as binding sites for specific bacterial adhesins.  Accordingly, the bacterial 
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adhesins will bind to the exogenous oligosaccharides rather than to the surface 
of the cell.  Reduced bacterial adherence may ultimately decrease infection. 
Several oligosaccharides have been reported to inhibit pathogen adherence.   
Mannan oligosaccharides have long been known to inhibit Type-1 fimbriae-
mediated adherence of Escherichia coli and Salmonella spp. (Firon, 1982; Kisiela 
et al., 2006; Neeser et al., 1986).  Galactooligosaccharides (GOS) were shown to 
inhibit adherence of enteropathogenic E. coli (EPEC), as well as the neonatal 
opportunistic pathogen, Cronobacter sakazakii.   Pectin oligosaccharides have 
been reported to reduce invasion of Campylobacter jejuni to Caco-2 cells (Ganan 
et al., 2010) as well as neutralize E. coli Shiga toxins (Olano-Martin et al., 2003). 
Oligosaccharides derived from human and bovine milk have also been shown to 
inhibit adherence of E. coli, Vibrio cholerae, and Salmonella fyris in various cell 
lines (Coppa et al., 2006), among others.   
Although the anti-adherence activity of several of these oligosaccharides against 
enteric pathogens has been assessed in vitro, testing biological activity in animal 
models requires that the pathogen is capable of colonizing and causing infection 
in the selected host.  While EPEC has been commonly used for in vitro 
adherence studies due to its ability to express multiple oligosaccharide binding 
adhesins, infection of conventional flora mice with EPEC strains does not result 
in high levels of EPEC colonization and shedding (Mundy et al., 2006).  
Therefore, the Citrobacter rodentium mouse model is now widely used as a 
surrogate to study EPEC and enterohemorrhagic E. coli (EHEC) pathogenesis in 
mice (Bishop et al., 2007; Mundy et al., 2005). C. rodentium is an attaching and 
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effacing (A/E) mouse pathogen whose virulence genes are encoded on a 
pathogenicity island known as the locus of enterocyte effacement (LEE), with 
very similar arrangements as the LEE found in EPEC and EHEC.  Thus, they 
share many virulence factors and colonization mechanisms (Deng et al., 2001; 
Mundy et al., 2005).  
In this study, we evaluated the ability of GOS to reduce adherence of C. 
rodentium, first, in vitro using a HEp-2 cell line, and then in vivo, in conventional 
flora and germ free C57Bl/6 mice.  We also assessed the ability of GOS to 
prevent or ameliorate the severity of disease pathologies in these mice.  
Materials and Methods 
Organisms and growth conditions Citrobacter rodentium DBS100Nalr 
(nalidixic acid resistant) was kindly provided by Dr. Allen Smith (USDA, ARS, 
Baltimore). Prior to each experiment, frozen stock cultures were plated on Luria 
Bertani (LB; Difco) agar containing 100 µg/ml of nalidixic acid (Sigma) (LB-Nal) 
and grown overnight at 37°C. A single colony was inoculated into LB Broth and 
incubated aerobically at 37°C for 18 hours. For in vitro antiadherence 
experiments, cells were harvested by centrifugation (3,184 x g for 8 minutes), 
washed once with phosphate buffered saline (PBS) pH 7.0, and re-suspended in 
minimal essential medium (MEM; Hyclone, Logan, Utah), supplemented with 
10% fetal bovine serum (FBS; Hyclone). MEM was pre-equilibrated overnight at 
tissue culture conditions (5% CO2, 95% relative humidity, 37°C). 
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For mouse experiments, a single colony was grown overnight at 37°C in LB 
broth. A 1% inoculum was transferred to fresh LB broth and incubated for 5 hours 
at 37°C, shaking at 200 rpm. Preliminary experiments show that C. rodentium 
DBS100 Nalr reaches mid to late log phase after 5 to 6 hour incubation and 
achieves a cell density of about 2.0 x 108 CFU/ml. Bacteria were concentrated by 
centrifugation to deliver 2.5 x 108 C. rodentium CFU in 100 µl of PBS. 
Animals 8-week old conventional flora (CF) C57Bl/6 female mice were obtained 
from Charles River. Thirty-six 8-week old germ free (GF) C57BL/6 mice were 
bred and maintained at the GF facility in the Life Sciences Annex facility at the 
University of Nebraska – Lincoln (UNL). Water and food were provided ad 
libitum. All animal studies were performed according to approved protocols by 
the Institutional Animal Care and Use Committee (IACUC) at UNL. 
Tissue culture cells HEp-2 cells were obtained from ATCC. Cells were grown in 
75 cm2 tissue culture flasks containing 25 ml of MEM supplemented with 10% 
FBS in a CO2 incubator at tissue culture conditions. Confluent HEp-2 cells were 
harvested by removing MEM and washing the cells once with PBS. 
Subsequently, 0.5 ml of a 0.25% Trypsin-EDTA solution was added followed by 
10 minute incubation at tissue culture conditions. After incubation, 0.5 ml of FBS 
were added to inactivate the trypsin. Cells were then seeded onto 12 mm 
diameter glass coverslips in 24-well tissue culture plates at approximately 3.6 × 
105 cells per well, and 500 μl of MEM supplemented with 10% FBS was added to 
each well. Plates were incubated under tissue culture conditions for about 20 
hours prior to the start of each experiment.  Before each experiment, cells were 
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viewed using an inverted microscope to establish that they had reached about 
70% confluency. 
Galactooligosaccharides (GOS) Purimune GOS (formerly GTC Nutrition) was 
prepared as a stock solution and filter sterilized through a 0.2µm membrane filter. 
For in vitro experiments, a stock solution of GOS was prepared at 100 mg/ml. 
Adherence Assays C. rodentium DBS100 Nalr was prepared as previously 
described. GOS at concentrations ranging from 10 to 50 mg/ml was mixed with 
bacterial cultures (108 CFU/ml) prior to addition to tissue culture cells. Autoclaved 
distilled water instead of GOS was used as a control. Plates were incubated for 
90 minutes at tissue culture conditions to allow for bacteria to adhere. Assays 
were done in duplicate and replicated 3 times (n=6). ANOVA with Tukey’s test 
was used for statistical analysis using GraphPad Prism5 Software. 
Culture Enumeration After incubation, cells were detached by addition of 0.1% 
Triton X-100, serially diluted and plated on LB-Nal and incubated overnight at 
37°C. 
GOS Tolerance and Protection Assay (CF Mice) A GOS tolerance assay was 
performed to determine if any GOS concentration would cause signs of distress 
in the mice. 25 mice were randomly divided into 5 groups (A,B,C,D,E) (5 mice 
per cage) and housed with food and water provided ad libitum. On average, a 
mouse consumes around 5 ml of water per day. Hence, GOS was provided in the 
drinking water to deliver the following doses of GOS based on 5 ml water 
consumption per mouse, per day: 140 mg GOS/kg body weight, 2500 mg 
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GOS/kg body weight, and 5000 mg/kg body weight, two weeks prior to 
inoculation with C. rodentium and during the course of infection (10 days). 
Treatment groups were divided as follows: A) Control (non-treated group); B) 
Infected control; C) 140 mg GOS/kg body weight; D) 2500 mg GOS/kg body 
weight E) 5000 mg GOS/kg body weight. Groups C, D, and E were dosed by oral 
gavage with 2.5 x 108 CFU of C. rodentium (DBS100Nalr) in 100 µl of PBS after 
two weeks of GOS supplementation.  
Fecal pellets were collected every other day starting on day one of GOS 
supplementation. Briefly, mice pellets were collected in sterile brown paper bags 
and transferred into sterile microcentrifuge tubes. To quantify C. rodentium 
shedding, pellets were weighed and homogenized in PBS, serially diluted, and 
plated on LB-Nal Agar.  
Necropsy was performed at day 10 post infection. Colon length was measured 
and 0.5 cm of the most distal portion was saved in 10% formalin for 
histopathology.  To assess adherence to intestinal tissue, the next 3 cm distal 
sections were cut and washed with PBS, homogenized in a gentleMACS 
dissociator (Miltenyi Biotec; San Diego, CA) with 0.1% Triton x-100 in PBS, 
serially diluted and plated in LB-Nal Agar for quantification of adhered C. 
rodentium. Cecal contents were collected in 2 ml freezing vials and kept at -80°C.  
GOS Protection Assay (CF and GF Mice) Mice were randomly divided into 4 
groups (A, B, C, D), with 4 mice per cage and two cages per group.  Mice were 
provided with food and water provided ad libitum. GOS was provided in the 
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drinking water to deliver 5000 mg/kg of body weight per mouse, based on 5 ml 
water consumption per mouse, per day, two weeks prior to inoculation with C. 
rodentium and during the course of infection (10 days). Treatment groups were 
divided as follows: A) Control (non-treated group); B) Infected control (C. 
rodentium infected); C) GOS control (non-infected, GOS supplemented); D) GOS 
treatment (GOS supplemented, C. rodentium infected). Groups B and D were 
dosed by oral gavage with 2.5 x 108 CFU of C. rodentium (DBS100Nalr) in 100 µl 
of PBS.  
Fecal pellets were collected every other day starting on day one of GOS 
supplementation and C. rodentium shedding was quantified as above.  
Necropsy was performed at day 10 post infection as above. Additionally, 3 cm of 
proximal colon were saved for tissue explants to evaluate pro and anti-
inflammatory cytokine expression.  
For the GF experiments, the same procedure was followed. Fecal collection was 
not performed every other day to assess bacterial shedding, only at day 10 post 
infection.  
Histopathology Colonic tissue was fixed in 10% formalin. Tissues were paraffin 
embedded, sectioned, and stained with hematoxylin and eosin (H&E). To assess 
pathology, a scoring system was adapted from Gibson et al., 2008. Tissue 
scoring was performed by a blinded observer as following: sub-mucosal edema 
(0=no change; 1=mild; 2=moderate; 3=profound), goblet cell depletion (number 
of goblet cells on 5 microscopic fields averaged, 400x magnification); epithelial 
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hyperplasia (as compared to normal height of a control / 0=no change; 1=1-50%; 
2=51-100%; 3=>100%), epithelial integrity (0=no change; 1=<10 epithelial cells 
shedding; 2=11-20 epithelial cells shedding; 3=ulceration of epithelium; 
4=ulceration accompanied with severe crypt destruction), neutrophil and 
mononuclear cell infiltration (0=none; 1=mild; 2=moderate; 3=severe). Adding up 
scores for each parameter gives the total pathology score, which can reach a 
maximum of 16. C. rodentium infected mice would elicit a pathology score 
around 6 to 8; scores greater than 8 indicate profound tissue damage due to 
infection.  
GraphPad Prism5 software was used for statistical analysis of the data. A 
Kruskal-Wallis test was performed with Dunns post-test to compare all pairs of 
columns; significant difference between treatments with p<0.05. 
Results 
GOS reduces adherence of C. rodentium DBS100 Nalr to HEp-2 cells  
Adherence of C. rodentium to HEp-2 cells was assessed in the presence and 
absence of GOS at concentrations ranging from 10 to 50 mg/ml. Adherence 
inhibition occurred at all concentrations in a dose-dependent manner.  At the 
lowest dose (10 mg/ml), a one log reduction in adherence was observed. As the 
GOS concentration increased, adherence was reduced nearly two logs with the 
highest concentration tested (50 mg/ml) (Fig. 1). 
GOS reduces adherence of C. rodentium DBS100Nalr to the colon of CF 
mice 
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A  GOS tolerance study was performed to evaluate mice tolerance to the 
different GOS doses, as well as to determine the effective GOS protective dose 
for subsequent experiments. Mice provided with or without GOS for two weeks 
were infected with C. rodentium.  After 10 days, mice were necropsied and 
adherence was assessed in 3 cm sections from the distal colon. Colon sections 
were homogenized, serially diluted, and plated in LB-Nal agar for bacterial 
enumeration. Results revealed that supplementation with GOS reduced 
adherence of C. rodentium to the surface of the proximal colon compared to the 
control (Fig. 2A).  Adherence inhibition was achieved when mice were 
supplemented with 2,500 mg GOS/kg body weight and 5,000 mg GOS/kg body 
weight, but not with the lowest dose of GOS tested, 140 mg GOS/kg body weight 
(Fig. 2A).  Shedding of C. rodentium in feces was assessed by serially diluting 
and plating samples on LB-Nal agar.  Shedding levels were the same for both the 
GOS-treated and untreated groups (data not shown). 
For the subsequent CF mouse experiment, a dose of 5,000 mg GOS/kg body 
weight was supplemented to the GOS treated mice. Adherence of C. rodentium 
was assessed in a 3 cm portion of the distal colon. The colon was homogenized, 
serially diluted and plated in LB-Nal agar for bacterial enumeration. Lower 
bacterial adherence was observed in the group supplemented with GOS as 
compared to the infected control (Fig. 2B). No difference in C. rodentium 
shedding in feces was observed between the infected groups (data not shown). 
In addition, GOS supplementation resulted in ameliorated colon shortening in the 
GOS treated group (data not shown). 
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GOS does not reduce adherence of C. rodentium DBS100 Nalr in GF mice 
Mice provided with or without GOS for two weeks were infected with C. 
rodentium.  After 10 days, mice were necropsied and adherence was assessed 
in 3 cm sections from the distal colon. Colon sections were homogenized, serially 
diluted, and plated in LB-Nal agar for bacterial enumeration. Adherence of C. 
rodentium was not reduced in the GOS supplemented group as compared to the 
infected control (Fig. 2C). There was no evidence of colon shortening in either 
the infected control, or the GOS-C. rodentium infected group, as compared to the 
non-treated group. 
GOS does not elicit protection in CF mice against C. rodentium DBS100Nalr 
associated disease 
At necropsy, a 0.5 cm section of the distal colon was fixed in 10% formalin, 
paraffin embedded, and H&E stained. Slides were assessed for lesions 
associated with C. rodentium infection. Parameters used to characterize the 
severity of disease included sub-mucosal edema, epithelial hyperplasia, epithelial 
integrity, goblet cell depletion, and neutrophil and mononuclear cell infiltration. 
The non-infected control groups did not show any signs of disease, as was 
expected. C. rodentium-infected groups showed typical signs of infection. Each 
parameter was evaluated independently, and significant differences were 
detected between the infected control and GOS supplemented – infected group. 
In addition, scores for all parameters were added up to obtain a total pathology 
score. No significant difference between the two groups was found, indicating 
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that GOS supplementation does not significantly reduce or prevent lesions 
caused by C. rodentium infection (Fig 3). 
Discussion 
In this study, we evaluated the ability of GOS to reduce adherence of C. 
rodentium DBS100Nalr in vitro and in vivo in CF and GF C57Bl/6 mice. In 
addition, we assessed the ability of GOS to prevent or mitigate the lesions 
associated with C. rodentium infection in mice.  
The results from the in vitro adherence experiments indicated that GOS inhibits 
adherence of C. rodentium DBS100Nalr to HEp-2 cells in a dose dependent 
manner.  These results are consistent with previous studies showing that GOS 
inhibits adherence of EPEC, C. sakazakii, and S. Typhimurium to the surface of 
epithelial cells in vitro in a similar dose-dependent manner (Shoaf et al., 2006; 
Quintero et al. 2011; Searle et al., 2009, 2010).   For C. rodentium, as well as 
EPEC, virulence factors are encoded on a LEE pathogenicity island, but in a 
slightly different arrangement (Deng et al., 2001). Although the C. rodentium 
adherence machinery has not been clearly established, LEE virulence factors are 
required for infection in CF mice (Kamada et al., 2012).  
We next tested for the ability of GOS to reduce adherence in vivo using CF and 
GF mice.  In mice, C. rodentium is the causative agent of murine colonic 
hyperplasia. The severity of the disease varies according to mouse strains. In 
C57Bl/6 mice, the lesions in affected animals include a grossly thickened distal 
colon, commonly devoid of formed feces.  In those cases in which the severity of 
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disease is increased, the cecum and ileum may also be affected. Microscopically, 
murine colonic hyperplasia is accompanied by colonic crypt elongation, goblet 
cell depletion, sub-mucosal edema, and neutrophil and mononuclear cell 
infiltration. The disease peaks around 7-10 days post-infection, clearing after 
about 6 weeks (Barthold, 1980; Luperchio and Schauer, 2001; Mundy et al., 
2005).  
Our results indicated that GOS supplementation significantly reduced C. 
rodentium adherence in the distal colon of CF mice. In addition, a reduction in the 
gross lesions of the colon, as assessed by colon shortening and lack of fecal 
pellets, was observed when mice were supplemented with GOS. However, only 
the highest doses were effective at reducing adherence and causing these 
pathological effects. Histological analysis of the distal colon of CF flora mice 
indicated typical signs of C. rodentium infection. Epithelial hyperplasia, goblet cell 
depletion, neutrophil and mononuclear cell infiltration, loss of epithelial cell 
integrity, and sub-mucosal edema were evident in groups infected with C. 
rodentium. Lesions were scored as previously described, and no protection from 
disease was evident in mice supplemented with GOS.  
The role that the commensal microbiota plays in controlling pathogen 
colonization has been well documented (Buffie and Pamer, 2013; Kamada et al., 
2013). The resident population can restrict pathogen access to host tissue either 
directly, by production of toxins and bacteriocins, or indirectly, by lowering colonic 
pH via secretion of short chain fatty acids (SCFA).  Collectively, these agents can 
result in inhibition of other competitors of the same or different bacterial species 
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(Buffie and Pamer, 2013; Hammami et al., 2013; Tejero-Sariñena et al., 2012). 
Dietary modulation of the gut microbiota due to consumption of GOS and other 
prebiotics has been shown to enhance the production of SCFA in the gut 
(Cummings and Macfarlane, 2007; Cummings et al., 2001). Hence, one 
mechanism by which GOS can prevent or reduce pathogen colonization, 
indirectly, is by modulating the gut microbiota, enhancing the production of 
SCFA, and lowering the environmental pH.  Nevertheless, no reduction in C. 
rodentium shedding in CF mice was observed among the infected groups (with 
and without GOS supplementation), suggesting the reduction in adherence of C. 
rodentium was likely not due to a bactericidal effect mediated by the microbiota.  
A GF mouse model was used to assess the effect of GOS on adherence of C. 
rodentium to the mouse colon, in the absence of the gut microbiota. Surprisingly, 
in contrast to the CF model, GOS did not reduce adherence of C. rodentium in 
the GF mouse colon. Evidently, the commensal microbiota was necessary for 
GOS to be effective as an anti-adherence agent. One mechanism pathogens 
employ to overcome colonization resistance is to occupy niches and adhere 
intimately to regions devoid of commensal bacteria. Thus, for EPEC, EHEC, and 
C. rodentium (Kamada et al., 2012, 2013), intimin, as well as other specialized 
virulence factors promote colonization by tightly binding to the epithelial cell 
lining. In the absence of a microbiota, all the niches become available.  Thus, 
expression of adherence factors becomes less critical to the success of the 
organism. 
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Moreover, it has been shown that C. rodentium colonizes at higher levels in GF 
mice as compared to CF mice (Kamada et al., 2012), suggesting that in the 
absence of the gut microbiota, more niches would be open in the GF mice, hence 
allowing C. rodentium to colonize elsewhere, in addition to tightly binding to the 
epithelial cell lining (Kamada et al., 2012). In addition, avirulent C. rodentium 
strains are known to colonize GF mice, but not CF mice (Kamada et al., 2012), 
suggesting that a specific niche may not be essential for colonization in the 
absence of the gut microbiota. Colonization of different tissues relies on the 
expression of different adhesins by the pathogen, that recognize specific 
receptors in the chosen binding site (Ofek et al., 2003); different binding sites 
require the expression of different adhesins. Therefore, in the absence of the 
microbiota, C. rodentium could be expressing other adherence factors targeted 
for colonization of other available niches, in addition to the expression of the 
virulence factors carried in the LEE island.  The latter are indistinctly expressed 
in C. rodentium colonization of GF or CF mice (Kamada et al., 2012). Hence, to 
reduce adherence of C. rodentium in the GF mouse colon, GOS might not be 
effective due to the other possible adhesins being expressed for colonization.  
Although the exact adherence and colonization mechanisms of C. rodentium 
have not been thoroughly characterized, some factors have been identified that 
are required for colonization of CF mice (Deng et al., 2003; Kamada et al., 2012; 
Mundy et al., 2003). Intimin and the translocated intimin receptor (Tir), two 
important LEE encoded proteins, have been shown to have crucial roles in 
pedestal formation in A/E lesions.  The mechanisms for pedestal formation have 
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been well established for EPEC and EHEC (Campellone, 2003; DeVinney et al., 
2001; Marches et al., 2000). Tir, in addition to its role in pedestal formation, has 
been shown to be essential for C. rodentium colonization of the CF mouse colon 
(Deng et al., 2003). The Ler promoter is responsible for the regulation of most 
LEE encoded genes, including Tir (Barba et al., 2005; Deng et al., 2001, 2004); 
Kamada et al., 2012 showed that C. rodentium ler mutants were unable to 
colonize CF mice. Although Tir has been shown to be essential for C. rodentium 
colonization, other LEE-encoded factors might also play a central role. In addition 
to the importance of LEE for colonization, a non-LEE encoded colonization factor 
has been characterized for C. rodentium. The colonization factor Citrobacter 
(CFC) is a gene cluster encoding a type IV pilus, and has been shown to be 
required for colonization (Mundy et al., 2003). Hence, it has been suggested that 
initial colonization of C. rodentium of locations other than colonic epithelial cells, 
could be mediated by a fimbrial adhesin (Wiles et al., 2004). The role of other 
factors, either LEE or non-LEE encoded, that might be involved in C. rodentium 
adherence and colonization have not been so far elucidated. Moreover, factors 
used for C. rodentium colonization and adherence in GF mice are not clear.  
Overall, this study shows that GOS may provide prophylactic protection against 
C. rodentium by reducing adherence of bacteria to epithelial cells in vitro as well 
as in vivo in a CF mouse model. Further research is required to elucidate the 
adherence mechanisms and factors required for C. rodentium colonization in GF 
mice. It is highly likely that GOS targets a specific factor used for adherence by 
C. rodentium, specifically expressed when colonizing CF mice and tissue culture 
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HEp-2 cells. The difference in adherence mechanisms in GF and CF mice should 
be further explored. If these are well characterized, other types of non-digestible 
oligosaccharides could be used to target different adhesins or adherence factors 
responsible for adherence to and colonization of the colonic epithelial cell lining.  
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Figure 1 Adherence of C. rodentium DBS100nalr to HEp-2 in the presence and 
absence of GOS. Treatments marked with an (*) are significantly different from 
the control (p<0.05). Treatments with different letters are significantly different 
from each other (p<0.05).  
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Figure 2 (A) Adherence of C. rodentium DBS100 Nalr to CF mice distal colon. 
Mice were supplemented with different doses of GOS and the groups are defined 
as follows (A) Non-treated group; (B) Infected control; (C) GOS 140 mg/kg body 
weight (infected); (D) GOS 2500 mg/kg body weight (infected); (E) GOS 5000 
mg/kg body weight (infected). Treatments with different letters are significantly 
different from each other (p<0.05). (B) Adherence of C. rodentium to CF mice 
distal colon. (GOS treatment: 5000 mg GOS/kg body weight). Groups with 
different letters are significantly different from each other (p<0.05). (C) 
Adherence of C. rodentium to GF mice distal colon. (GOS treatment: 5000 mg 
GOS/kg body weight). Groups with different letters are significantly different from 
each other (p<0.05). 
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Figure 3 Total histopathological score of CF mice distal colon. Treatments with 
different letters are significantly different from each other (p<0.05). 
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Chapter 5 
Biological Properties of Yeast-derived Mannan Oligosaccharides: 
Antiadherence and Prebiotic Activity 
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Abstract 
Non-digestible oligosaccharides have been shown to have several biological 
properties that can contribute to host health. Some are classified as prebiotics 
and stimulate the growth of specific members of the gut microbiota and enhance 
production of short chain fatty acids (SCFA).  In contrast, others are able to 
inhibit pathogen adherence to the surface of epithelial cells and thereby reduce 
infection and carriage.  Yeast-derived mannan oligosaccharides (MOSy) are 
widely used in animal feed as health and growth promoters.  However, their anti-
adherence and prebiotic activities have not been established. In this study, the 
soluble fraction of MOSy was tested for its ability to reduce adherence of Vibrio 
cholerae, the causative agent of cholera.  Anti-adherence experiments were 
done using HEp-2 cells at different concentrations of MOSy.  In addition, MOSy 
was subjected to in vitro digestion and human fecal fermentations to assess their 
bifidogenic effect and the ability to stimulate the production of short chain fatty 
acids (SCFA). Results indicated that MOSy inhibited adherence of V. cholerae at 
a minimum concentration of 1 mg/ml in a dose-dependent manner. In addition, 
after 12 hours of fecal fermentation, growth of bifidobacteria was stimulated, and 
production of SCFAs (acetate, butyrate and propionate) was increased, 
compared to a control (no carbohydrate added) fermentation. Acetate was 
produced in the highest proportion, followed by propionate and then butyrate. 
This suggests that the soluble fraction of MOSy possesses anti-adherence 
activity against V. cholerae and also has prebiotic activity. Therefore, this 
material could be used as a prophylactic ingredient to prevent the onset of 
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cholera in areas where the disease remains endemic, as well as contribute to 
overall gut health.  
 
Key Words: mannan oligosaccharides, anti-adherence, Vibrio cholerae, prebiotic
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Introduction 
 Prebiotic oligosaccharides are defined as selectively fermented 
ingredients that allow specific changes, both in the composition and/or activity in 
the gastrointestinal microflora that confer benefits upon host well-being and 
health (Gibson et al., 2010). A similar group of substances, referred to as non-
digestible oligosaccharides (NDOs), have been shown to have biological 
properties that confer health benefits on the host, but that do not necessarily 
meet the definition of a prebiotic.  Among the NDOs that have received much 
commercial and research interests are the mannan oligosaccharides (MOS).  
Most commercial MOS are derived from yeast cell walls, mainly Saccharomyces 
cerevisiae (Tassinari et al., 2007).   They are manufactured and marketed as cell 
extracts, containing unmodified cell walls, or are partially purified containing 
primarily MOS and glucans (Spring et al., 2000). The latter are the most common 
MOS products among the animal feed industry. The process of purification 
involves yeast cell lysis, followed by centrifugation and isolation of the cell wall 
components.  They are then washed and spray dried (Hill et al., 2008; Spring et 
al., 2000). 
  Most of the research on the biological and functional properties of MOS 
has been done with livestock, including broiler chickens and weanling pigs.  
Properties attributed to MOS include immune modulation, as well as inhibition of 
pathogen adherence to the surface of epithelial cells (Heinrichs et al., 2003; 
Muchmore et al., 1990; Newman et al., 1994; Savage et al., 1996).  These 
activities may therefore provide protection of the host against colonization by 
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intestinal pathogens in the animals.  In addition, MOS supplementation in animal 
feed has been shown to support overall animal health, including increased feed 
intake and enhanced growth performance (Davis et al., 2000; Pettigrew, 2000). 
Despite these biological properties, MOS are not generally fermented by the 
colonic microbiota of livestock (Fairchild et al., 2001; Flickinger et al., 2003).  
There is also very little information regarding the ability of the human colonic 
microbiota to ferment MOS.  
 Some bacterial adhesins, such as the Type 1 fimbriae produced by 
Salmonella spp. and Escherichia coli, are known to be mannose sensitive. Thus 
in the presence of free mannose, Type 1-mediated adherence to host cell tissues 
is inhibited (Firon, 1982; Kisiela et al., 2006; Neeser et al., 1986).  For example, 
in vitro studies have shown that yeast-derived mannoproteins inhibit adherence 
of Campylobacter jejuni to a Caco-2 tissue culture cell line (Ganan et al., 2009).  
Moreover, the addition of mannose and its derivatives has been shown to inhibit 
adherence of E. coli to epithelial cells, as well as inhibit adherence and further 
colonization of the mouse urinary tract (Aronson et al., 1979; Ofek and Beachey, 
1978). 
 Another group of NDO that has been well studied is the 
galactooligosaccharides (GOS).  These are widely used in food applications due 
to their prebiotic activity.  However, in addition to their ability to modulate the 
gastrointestinal microbiota, GOS have also been shown to reduce adherence of 
pathogens to epithelial cells in vitro and in vivo (Quintero et al., 2011; Searle et 
al., 2009, 2010; Shoaf et al., 2006). In addition, GOS have been shown to inhibit 
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binding of the Vibrio cholerae toxin to its cell surface receptor (Sinclair et al., 
2009).  
 V. cholerae is the causative agent of cholera, an enteric infection caused 
by the ingestion of water contaminated with the organism (Reidl and Klose, 
2002). Cholera is endemic in many parts of the world (Codeco, 2001).  The most 
frequently affected areas generally consist of low income and other vulnerable 
populations, often following exposure to natural disasters when poor sanitation 
conditions exist. Although the mechanism by which V. cholerae adheres to the 
surface of cells has not been clearly established, it appears clear that intestinal 
adherence and colonization are essential steps in the infection process (Jones et 
al., 1976; Nelson et al., 1976) . Jones and Freter, 1976 proposed that flagella are 
required for adherence, not necessarily for the bacteria to come in contact with 
the cells, but due to an adhesin carried in the tip of the flagella.  Thus, 
prophylactic approaches based on preventing or interfering with adhesins 
necessary for initial adherence may be effective at reducing infections caused by 
this organism.  
 In this study, the soluble fraction obtained from a commercial source of 
yeast cell wall-derived mannan oligosaccharides was tested for its ability to 
inhibit V. cholerae at the surface of tissue culture epithelial cells. In addition, the 
fraction was characterized for its ability to resist digestion in vitro and serve as a 
substrate during in vitro fermentations.  Moreover, GOS were also assessed for 
their ability to reduce adherence of V. cholerae to the tissue culture epithelial 
cells.  
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Materials and Methods 
Organisms and growth conditions Vibrio cholerae ATCC 14035 was obtained 
from the American Type Culture Collection (ATCC, Manassas, VA). Prior to each 
experiment, frozen stock cultures were plated onto Tryptic Soy Agar (TSA; Difco) 
and grown overnight at 37°C. A single colony was inoculated into Tryptic Soy 
Broth (TSB; Difco) and incubated aerobically, at 37°C, without shaking for 18 
hours. Cells were harvested by centrifugation (3,184 x g for 8 minutes), washed 
once with phosphate buffered saline (PBS) pH 7.0, and re-suspended in minimal 
essential medium (MEM; Hyclone, Logan, Utah), supplemented with 10% fetal 
bovine serum (FBS; Hyclone). MEM was pre-equilibrated at tissue culture 
conditions (5% CO2, 95% relative humidity, 37°C).  
Yeast cell wall-derived Mannan oligosaccharides (MOSy) MOSy were 
obtained from Lallemand (Ontario, Canada) as a powdered material. A stock 
solution was prepared by mixing 100 mg of powder per ml of distilled water. To 
separate the soluble fraction, the stock solution was centrifuged (201 x g for 10 
minutes) and the supernatant was collected, filtered through a 0.4 µm filter, and 
subsequently freeze dried. Stock solutions from the freeze dried material were 
prepared as required for adherence experiments.  This material contained about 
60% protein and 30% carbohydrate. 
Galactooligosaccharides (GOS) Purimune GOS were obtained from GTC 
Nutrition. The powder contained 92% GOS with background sugars including 
lactose (7%) and glucose and galactose (1%). GOS was prepared as a stock 
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solution (100 mg/ml) in distilled water and filter sterilized using 0.22 µm 
membrane filters.  
Mannose D-(+)-mannose (Sigma) was prepared as a stock solution at a final 
concentration of 100 mg/ml in distilled water. The solution was filter sterilized 
using 0.22 µm membrane filters. 
Tissue culture cells HEp-2 cells were obtained from ATCC. Cells were grown in 
75 cm2 tissue culture flasks containing 25 ml of MEM supplemented with 10% 
FBS in a CO2 incubator at tissue culture conditions. Confluent HEp-2 cells were 
harvested by removing MEM and washing the cells once with PBS. 
Subsequently, 0.5 ml of a 0.25% Trypsin-EDTA solution was added followed by a 
10 minute incubation at tissue culture conditions. After incubation, 0.5 ml of FBS 
were added to inactivate the trypsin. Cells were then seeded onto 12 mm 
diameter glass coverslips in 24-well tissue culture plates at approximately 3.6 × 
105 cells per well, and 500 μl of MEM supplemented with 10% FBS was added to 
each well. Plates were incubated under tissue culture conditions for about 20 
hours prior to the start of each experiment. Cells were checked before the 
experiment under an inverted microscope to make sure they had reached about 
70% confluency. 
Adherence Assays V. cholerae was grown and harvested as described above. 
MOSy was mixed with bacterial cultures at a concentration of 108 CFU/ml prior to 
addition to tissue culture cells. Distilled autoclaved water was added as a control 
instead of MOSy.  Bacteria mixed with MOSy were added to the cells and plates 
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were incubated for 30 minutes at tissue culture conditions. Assays were done in 
duplicate and replicated 3 times (n=6). ANOVA was used to compare treatments 
to the control and Tukey’s test to compare all treatments using GraphPad Prism5 
software.  
Quantitative PCR (qPCR). qPCR was used for enumeration of adhered V. 
cholerae cells. Bacterial cells from adherence assays were detached by the 
addition of 1 ml of 0.1% Triton X-100 for 30 minutes at room temperature. 
Bacterial cells were harvested and centrifuged for 5 min at 10,000 x g, 
supernatants were discarded, and pellets were resuspended in 180 µl of buffer 
ATL from the DNeasy Blood and Tissue Kit (Qiagen, Hilden, Germany).  
Instructions provided in the manufacturer’s manual for DNA extraction of Gram 
negative bacteria were followed.  
Species-specific forward (5’-CACCAAGAAGGTGACTTTATTGTG-3’) and 
reverse (5’-GAACTTATAACCACCCGCG-3’) primers described by Nandi et al. 
(Nandi et al., 2000) were used. A standard curve was prepared with known cell 
counts of V. cholerae. DNA was extracted as previously described. The qPCR 
was performed using a Mastercycler Realplex2 (Eppendorf AG, Hamburg, 
Germany). Each PCR was conducted in a 25 µl volume. The reaction mixture 
comprised 11.25 µl of 20x SYBR solution and 2.5-µl Real-MasterMix (5Prime), 
0.5 µM of each primer, and 1µl of DNA template. The program consisted of an 
initial denaturation step at 94°C for 5 min, and 30 cycles of denaturation at 94°C 
for 30 sec, 64°C for 30 sec for annealing, and 68°C for 30 sec for extension. 
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The percent (%) inhibition was calculated as the control (adhered V. cholerae 
without MOS) minus the treatment (adhered V. cholerae with MOS), divided by 
the control, times 100. Detection limit was determined and prepared by running 
DNA samples of known V. cholerae concentration. Standard curve was prepared 
from DNA extracted from V. cholerae pure culture at a known concentration.  
In vitro digestion Gastric and small intestine digestions were simulated in vitro 
for MOSy as described by (Mishra and Monro, 2009), with modifications. MOSy 
(1 g) was added to a 50 ml screw cap conical tube and 12 ml of water was 
added. Digestion was started by adding 400 µl of 10% pepsin (Sigma) dissolved 
in 50 mM HCl.  The pH was adjusted to 2.5 with 1 M HCl. Tubes were placed in a 
water bath at 37°C, incubated for 30 min, shaking at 130 rpm. Subsequently, 800 
µl of 1 M sodium bicarbonate, 2 ml of 0.1 M sodium maleate buffer (pH 6, 
containing 2.5 mM CaCl2), and 2 ml of 2.5% pancreatin (Sigma) dissolved in 
sodium maleate buffer were added. The tubes were further mixed for 120 min at 
130 rpm. Following digestion, samples were dialyzed (500 molecular weight 
cutoff) and freeze dried.  
In vitro fermentation In vitro human fecal fermentations were performed in an 
anaerobic chamber (Bactron X, Sheldin Manufacturing, Cornelius, OR).  First, 
150 mg of digested, freeze-dried MOSy (see above) were transferred into 50 ml 
screw cap Erlenmeyer flasks.  Flasks containing inulin or no added carbohydrate 
were also included as positive and negative controls. Then, 8 ml of Nutrient 
Basal Media (NBM) (Hartzell et al., 2013) were added to each flask. Fecal 
samples were collected from volunteers in the Department of Food Science and 
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Technology at the University of Nebraska – Lincoln and immediately transferred 
to the anaerobic chamber to prepare the fecal slurry. The subjects had no 
reported symptoms of gastrointestinal distress or disease and had not used 
antibiotics for the previous three months. Slurries were prepared by diluting 
pooled portions from three subjects 1:10 in PBS using a hand blender.  Then, 2 
ml of fecal slurry were added to each flask. Flasks were incubated at 37°C 
shaking at 130 rpm. Samples (1 ml) were collected in 1.5 ml microcentrifuge 
tubes at 0 (baseline), 8, 12, and 24 hours, centrifuged (10,000 x g for 3 min), and 
frozen at -80°C for microbial analysis.  
Bifidobacteria and lactobacilli quantification  
DNA was extracted from the samples using the phenol-chloroform method 
described by Martinez et al. (2009). Incubation times were increased to 30 
minutes. Populations of bifidobacteria and lactobacilli were quantified by qPCR 
as described above. Bifidobacterium-specific forward (5’ 
TCGCGTCYGTGTGAAAG 3’) and reverse (5’ CCACATCCAGCRTCCAC 3’) 
primers were used for detection of bifidobacteria. The amplification program used 
consisted of an initial denaturation at 95°C for 10 min, followed by 35 cycles of 
denaturation at 95°C for 15 sec, annealing at 58°C, and extension at 68°C for 60 
sec. Standard curves were prepared using overnight cultures of Bifidobacterium 
adolescentis IVS-1 at known concentrations. Lactobacillus-specific forward (5’ 
AGCAGTAGGGAATCTTCCA 3’) and reverse (5’ ATTYCACCGCTACACATG 3’) 
primers were used for detection of lactobacilli. The amplification program 
consisted of an initial denaturation at 95°C for 10 min, followed by 40 cycles of 
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denaturation at 95°C, annealing at 61°C, and extension at 68°C for 60 sec. 
Standard curves were prepared using overnight cultures of Lactobacillus reuteri 
DSM 17938 (BioGaia, Stockholm, Sweden) at known concentrations.  
Short chain fatty acid (SCFA) analysis 
Samples (900 µl) were collected after 12 hours of fermentation for SCFA 
analysis, 100 µl of phosphate buffer (0.8 M, pH 2.0) were added, and 
immediately frozen at -80°C. For SCFA analysis, samples were prepared, as 
described by Pollet et al., 2012 with modifications.  Briefly, samples were thawed 
at room temperature, and 400 µl were transferred to a 2 ml microcentrifuge tube 
containing sulfuric acid (200 µl, 9 M), sodium chloride (~0.16 g), and internal 
standard (100 µl of 7 mM 2-ethyl butyrate in 2 M KOH). Immediately before 
injection into the GC, diethyl ether (500 µl) was added to the tubes, mixed well, 
and centrifuged at 10,000 x g for 3 min. The diethyl ether phase was collected 
and placed into glass vials. SCFAs were measured by gas chromatography (GC) 
as described by Hartzell et al., 2013. Standards were injected and response 
factors for each SCFA relative to 2-ethyl butyric acid were calculated for 
quantification.  
Results 
MOSy, but not the mannose monomer, inhibits adherence of V. cholerae to 
HEp-2 cells  
 Adherence assays were performed using a HEp-2 cell line as previously 
described.  MOSy solutions were prepared from the initial stock in concentrations 
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ranging from 0.5 to 50 mg/ml. Mannose solutions were prepared from the initial 
stock in concentrations ranging from 10 to 50 mg/ml. Adherence in the presence 
and absence of MOSy and mannose was measured by qPCR. Significant 
adherence inhibition was observed at a minimum concentration of 1 mg/ml MOSy 
and increased with higher concentrations. No additional inhibition was observed 
when a concentration of 4 mg/ml was reached as compared with all the higher 
concentrations tested (Fig. 1). In contrast, the mannose monomer had no effect 
on adherence of V. cholerae to HEp-2 cells (Fig. 2).   
GOS does not inhibit adherence of V. cholerae to HEp-2 cells 
Adherence assays were performed using a HEp-2 cell line as previously 
described.  GOS solutions were prepared from the initial stock in concentrations 
ranging from 10 to 50 mg/ml. Adherence in the presence and absence of GOS 
was measured by qPCR. No reduction in adherence of V. cholerae was observed 
in the presence of GOS (Fig. 3). 
MOSy increases bifidobacteria levels but not lactobacilli in in vitro 
fermentations 
The bifidogenic effect of MOSy was assessed in vitro with fecal samples 
obtained from three different donors. Inulin was used as a positive control. The 
levels of bifidobacteria were assessed after 8, 12, and 24 hours of fermentation 
compared to the baseline (0 hours) and the control (no carbohydrate added). 
Results indicated that 1.5% MOSy significantly stimulated the growth of 
bifidobacteria in human fecal samples after 12 hours of fermentation as 
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compared to the baseline and the control (Fig. 4). However, no significant 
differences were observed at 8 and 24 hours of fermentation (data not shown). 
Lactobacillus levels were also assessed after 8,12, and 24 hours of fermentation 
and compared to the baseline (time 0) and the control. No significant differences 
were observed for any of the time points (data not shown).  
MOSy increases production of SCFA 
SCFA were measured after 12 hours of fermentation. Concentrations of total 
SCFA (butyrate + acetate + propionate) in samples from the fermentations with 
added carbohydrate and with the control were determined. The total SCFA 
production in the presence of inulin (positive control) and MOSy was significantly 
different from the control. No significant difference in total SCFA production 
between inulin and MOSy was observed. Significant differences were observed 
among the different types of SCFAs between inulin and MOSy. Propionate was 
significantly higher in the MOSy treatment, whereas butyrate was significantly 
higher in the inulin treatment. No significant differences were observed in the 
production of acetate with the two carbohydrates (Fig. 5). 
Discussion 
 There is now considerable public health interest in identifying prophylactic 
strategies to prevent or reduce gastrointestinal infections caused by enteric 
pathogens.  One such approach, using molecular decoys to inhibit pathogen 
adherence, was proposed more than a decade ago (Cozens and Read, 2012; 
Sharon and Ofek, 2000, 2002).  This is an attractive approach since several 
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food-grade ingredients, including prebiotics and NDOs, have been shown to 
inhibit pathogen binding to the surface of intestinal cells in vitro and in vivo. In 
these studies, adherence of enteropathogenic E. coli (EPEC), Salmonella 
Typhimurium, and C. sakazakii was reduced by GOS in vitro (Quintero et al., 
2011; Searle et al., 2009; Shoaf et al., 2006). In addition, Searle et al., 2009 
showed that GOS reduced adherence of S. Typhimurium in mice. Moreover, 
GOS was also shown to prevent binding of cholerae toxin to its receptor in host 
cells (Sinclair et al., 2009). Other studies have shown that yeast-derived 
mannoproteins inhibit adherence of C. jejuni to a Caco-2 cell line (Ganan et al., 
2009) and mannose and its derivatives inhibit adherence of E. coli to epithelial 
cells (Ofek and Beachey, 1978). These studies led us to consider whether MOSy 
and GOS would be effective at reducing adherence of V. cholerae, an enteric 
pathogen responsible for 3–5 million cases and 100,000–120,000 deaths every 
year.  
 In this study, adherence of V. cholerae was assessed in the presence of 
MOSy and mannose, the monomer of MOSy, as well as GOS. Our results show 
that MOSy inhibits adherence V. cholerae to the surface of HEp-2 cells. 
Interestingly, mannose did not inhibit adherence of V. cholerae, suggesting that a 
special structural conformation of the mannose monomers might be required to 
inhibit V. cholerae adherence. Nevertheless, this is consistent with other reports 
showing that D-mannose does not reduce adherence of V. cholerae to rabbit 
brush borders (Jones and Freter, 1976). Moreover, our results indicated that 
GOS does not reduce adherence of V. cholerae to the surface of HEp-2 cells. 
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Interestingly, it has been shown that GOS prevents cholerae toxin from binding to 
its GMP1 receptor (Sinclair et al., 2009), suggesting that GOS might resemble 
the structure to which cholerae toxin binds, but not the receptor that V. cholerae 
recognizes for adherence and colonization. In addition to the ability to inhibit 
adherence, MOSy was also assessed for its prebiotic properties. MOSy was 
subjected to in vitro digestion and human fecal fermentation to determine if it 
confers a bifidogenic effect. It has been well established that prebiotics, such as 
inulin, increase levels of bifidobacteria in human fecal fermentations (Rao, 1999; 
Wang and Gibson, 1993) and in vivo in human studies (Gibson et al., 1995; 
Ramirez-Farias et al., 2009). Nevertheless, the ability of MOSy to stimulate the 
growth of bifidobacteria in vitro with human fecal samples had not yet been 
assessed. In this study, we demonstrated that 1.5% MOSy stimulates the growth 
of bifidobacteria, which is one of the bacterial species most commonly targeted in 
prebiotic research, since they are considered beneficial to gut health (Gibson et 
al., 2004). 
 While stimulating the growth of specific members of the gut microbiota, 
prebiotics or NDOs are fermented mainly to SCFAs, principally acetate, 
propionate, and butyrate. SCFAs have been shown to be beneficial to the host in 
multiple ways. They have been shown to enhance colonic metabolism and 
function by serving as an energy source for the colonic epithelium (Flint et al., 
2012). Butyrate has also been suggested to have anti-cancer and anti-
inflammatory properties (Flint et al., 2012; Hamer et al., 2008). Therefore, 
ingredients that stimulate the production of SCFAs could have a positive impact 
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on gut health and physiology. In this study, we demonstrated that MOSy 
stimulated the production of total SCFAs (butyrate, propionate, and acetate), 
suggesting that MOSy consumption as a prebiotic can positively impact gut 
health. 
The amount of each type of SCFA was also analyzed. MOSy stimulated the 
production of acetate to a greater extent than propionate and butyrate. Acetate 
has been shown to be released and become available systemically, in contrast to 
butyrate, which is consumed mainly by the colonic epithelium (Flint et al., 2012), 
hence their effects are also different. Acetate promotes and increases colonic 
blood flow and enhances motility in the ileum, while butyrate has been shown to 
be a preferred energy source for colonocytes and play a role in preventing 
certain types of colitis (Scheppach, 1994). Almost invariably, acetate reaches the 
highest concentration among the different SCFAs, and it is known to act as an 
intermediate that is utilized by butyrate-producing bacterial species in the gut 
(Louis and Flint, 2009).  
 Yeast-derived mannan oligosaccharides are commonly used in the animal 
feed industry to promote health and growth of livestock animals. Besides being 
used as a health promoter for livestock, MOSy has been shown to have other 
biological properties, which can be targeted to promote not only animal, but also 
human health if used as a food ingredient/prebiotic. Prophylactic approaches to 
prevent or mitigate bacterial infections are warranted, since antibiotic resistance 
in bacterial pathogens is rapidly increasing and has become a topic of public 
concern. MOSy could be proposed as a prophylactic agent to prevent or mitigate 
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V. cholerae infections, although further research is needed to determine if it could 
also be used to target other bacterial pathogens. In addition, MOSy could be 
used as a prebiotic to promote gut health and stimulate the growth of beneficial 
members of the gut microbiota.  
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Figure 1 % adherence inhibition of V. cholerae to HEp-2 cells by MOSy. ANOVA 
with Tukey’s post-test was used for statistical analysis (n=6). Treatments marked 
with an (*) are significantly different from the control. Treatments with different 
letters are significantly different from each other.  
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Figure 2 Adherence of V. cholerae to HEp-2 cells in the presence and absence 
of Mannose. ANOVA with Tukey’s post-test was used for statistical analysis 
(n=6). No treatments differed significantly from the control (α=0.05). 
 
 
 
 
 
 
 
 
 
 
   185 
 
 
  
Mannose (mg/ml)
L
o
g
 1
0
 (
C
F
U
/m
l)
0 10 20 30 40 50
5.0
5.5
6.0
6.5
7.0
 
 
 
 
   186 
 
 
  
Figure 3 Adherence of V. cholerae to HEp-2 cells in the presence and absence 
of GOS. ANOVA with Tukey’s post-test was used for statistical analysis (n=6). No 
treatments differed significantly from the control (α=0.05). 
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Figure 4. Enumeration of bifidobacteria in human fecal in vitro fermentation, in 
the presence of 1.5% inulin (positive control) or 1.5% MOSy or absence of 
carbohydrate (negative control) after 12 hours of fermentation. ANOVA with 
Tukey’s post-test was used for statistical analysis (n=3). Significant differences 
from the control are indicated with an *. Treatments with different letter are 
significantly different from each other (α=0.05).  
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Figure 5. Analysis of SCFA concentration after 12 hours of in vitro human fecal 
fermentation. Significant differences are shown with different letters within SCFA 
type. For total SCFA production, samples marked with an (*) are significantly 
different from the control (n=3, α=0.05). 
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Chapter 6 
Conclusions 
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 In this research we established that NDOs reduce adherence of 
pathogens to epithelial cells. Specifically, CHOS reduced adherence of EPEC to 
a HEp-2 cell line, as well as lactoferrin reducing adherence of C. sakazakii. In 
addition, MOSy reduced adherence of V. cholerae in a dose-dependent manner. 
Moreover, GOS was shown to reduce adherence of C. rodentium to the distal 
colon of conventional flora mice but not to germ-free mice. The major findings of 
this research and proposed future experiments are described below.  
 Different fractions of CHOS effectively reduced adherence of EPEC to 
HEp-2 tissue culture cells. 
 FA and DP were not determinant in the ability of CHOS to reduce 
adherence of EPEC in tissue culture cells.  
 An oligomeric conformation is required for CHOS to inhibit EPEC 
adherence, since the monomers did not exhibit any antiadherence activity. 
 Lactoferrin, alone and in combination with a blend of GOS-PDX, reduced 
adherence of C. sakazakii in tissue culture experiments. 
 No synergistic effect was observed in reducing adherence of C. sakazakii 
when lactoferrin was mixed with a blend of GOS-PDX. 
 GOS reduced adherence of C. rodentium to the surface of tissue culture 
HEp-2 cells at different concentrations. 
 GOS reduced adherence of C. rodentium to the distal colon of 
conventional C57Bl/6 mice. 
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 Supplementation with GOS did not ameliorate lesions caused by C. 
rodentium in conventional C57Bl/6.  
 GOS did not reduce adherence of C. rodentium to the distal colon of germ 
free mice.  
 MOSy effectively reduced adherence of V. cholerae to HEp-2 cells in a 
dose dependent manner. 
 MOSy increased bifidobacteria levels in human fecal in vitro fermentations 
as compared to the control and the baseline.  
 MOSy increased the production of SCFA in human fecal in vitro 
fermentations, as compared to the control. 
 GOS did not reduce adherence of V. cholerae to HEp-2 cells. 
 Collectively, these results suggest that NDOs are suitable food ingredients 
to be used to prevent adherence of enteric pathogens, likely by acting as 
molecular decoys, hence preventing or mitigating the onset of an infection.  
 The results from the in vivo experiments open further questions on 
understanding how NDOs inhibit adherence in the presence and absence of the 
gut microbiota, as well as the mechanisms by which C. rodentium causes 
infection in the two models. The expression of C. rodentium adhesins during 
colonization of germ-free and conventional flora mice requires further study. The 
differential expression of adhesins allows pathogens to colonize different tissues 
and different niches that have diverse cellular receptors to which they bind. 
Determining which adhesins are expressed by C. rodentium in the absence of 
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the gut microbiota, and identifying its target sites, can help target adherence with 
different NDOs than the ones used in this experiment. 
 
 
 
 
 
 
 
